Podcasts about Obesity

We love to hear from our listeners. Send us a message. On this week's episode of the Business of Biotech, Alex Aravanis, M.D., Ph.D., CEO of Moonwalk Biosciences, talks about the opportunity in obesity beyond GLP-1s. He describes Moonwalk's adipose-targeted siRNA strategy, the genetics-driven logic behind its targets, and what it takes to fund and build a clinical-stage company. Alex also discusses Moonwalk's recent $70 million Series B raise, using AI to prioritize targets and improve siRNA design, and how weight loss without appetite suppression could preserve lean muscle mass and improve tolerability. Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at lifescienceleader.com.  Subscribe to our monthly Business of Biotech newsletter. Get in touch with guest and topic suggestions: ben.comer@lifescienceleader.comFind Ben Comer on LinkedIn: https://www.linkedin.com/in/bencomer/

Dr. Richard Conway Bariatric Surgery 'Curing' Arthritis?: https://youtu.be/W2-0RkyGqcc Dr. David Liew Managing Muscle and Fat Loss with GLP-1s: https://youtu.be/fLCDLuJGyPA Daric Mueller (PA-C) GLP-1s and History of Thyroid Cancer?:https://youtu.be/H_UlthPGN6Y Dr. Bella Mehta How Weight Loss Changes the Course of Knee Osteoarthritis: https://youtu.be/Jg0hflvIMEo

Spencer Hecht, a former trial attorney turned Divorce Concierge, to break down everything that happens between the moment a marriage ends and the moment you walk into a lawyer's office, and why that period can make or break your entire case. Spencer shares what he's learned from years in the courtroom and now working directly with clients navigating the most high-conflict phase of separation. From the psychology of divorce to the role social media plays in destroying modern marriages, this conversation pulls no punches. ————————————————————

Another ESC recap, listener feedback on two trials, and a paper on GLP-1 effects on inflammation from the SELECT trial are the topics John Mandrola, MD, discusses in this week's podcast. This podcast is intended for healthcare professionals only. To read a partial transcript or to comment, visit: https://www.medscape.com/twic I Correction on PROFID Trial II Listener Feedback III Fifth Universal Definition of MI Fifth Universal Definition of MI https://doi.org/10.1093/eurheartj/ehag101 Foy/Mandrola Editorial on Troponin Use and Interpretation https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2777967 IV New ESC HF Guidelines ESC Guidelines for Management of HF https://doi.org/10.1093/eurheartj/ehag100 Sanjay Kaul on X https://x.com/kaulcsmc/status/2094959683215958158?s=20 Geographic Disparities in TOPCAT https://pmc.ncbi.nlm.nih.gov/articles/PMC5065247/ V AIR STEMI Trial AIR-STEMI Trial https://www.nejm.org/doi/full/10.1056/NEJMoa2605373 CR Strategies After MI https://www.jacc.org/doi/10.1016/j.jacc.2024.04.051 PRAMI Trial https://www.nejm.org/doi/full/10.1056/NEJMoa1305520 COMPLETE Trial https://www.nejm.org/doi/full/10.1056/NEJMoa1907775 FULL REVASC Trial https://www.nejm.org/doi/full/10.1056/NEJMoa2314149 VI GLP-1 News – A SELECT Trial Secondary Analysis Semaglutide and hsCRP in Patients with CVD and Obesity https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.125.074482 The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington Questions or feedback, please contact news@medscape.net

Welcome to the latest Midlife Minute. This episode unpacks ongoing research on Lp(a), explores how women's lipids change during the perimenopause-to-menopause transition, and clarifies what we can do about it. Stay tuned for more! IN THIS EPISODE, YOU WILL LEARN: How total cholesterol, LDL, and ApoB tend to rise most steeply around the final menstrual period, rather than increasing gradually with chronological aging Why women should have their Lp(a) checked both before and after menopause How oral and transdermal estradiol can affect LDL, HDL, triglycerides, and Lp(a) differently Why I recommend including ApoB when checking your lipids during the perimenopause window How your lifestyle can reduce your cardiovascular risk, even when your Lp(a) is elevated Why omega-3 fatty acids and commonly used lipid medications do not lower Lp(a) Why supplements are not replacements for statins in genuinely high-risk patients  I review the various PCSK9 inhibitors currently available, how they are administered, and their effects  How a CAC, a CT angiogram, and an AI-assisted CT angiogram can help women and their providers determine how aggressive their approach should be when Lp(a) is elevated Connect with Cynthia Thurlow   Follow on X, Instagram & LinkedIn Check out Cynthia's website. Submit your questions to support@cynthiathurlow.com  Join other like-minded women in a supportive, nurturing community: The Midlife Pause/Cynthia Thurlow.  Purchase Cynthia's book, The Menopause Gut. Cynthia's Intermittent Fasting Transformation Book The Midlife Pause Supplement Line References: 1. Menopause Transition and Cardiovascular Disease Risk: Implications for Timing of Early Prevention: A Scientific Statement From the American Heart Association.Circulation. 2020. El Khoudary SR, Aggarwal B, Beckie TM, et al.Guideline 2. Menopause: A Cardiometabolic Transition. The Lancet. Diabetes & Endocrinology. 2022. Nappi RE, Chedraui P, Lambrinoudaki I, Simoncini T.Review 3. Dyslipidemia Across the Menopause Transition: Mechanisms, Trajectories, and Opportunities for Cardiovascular Prevention. Maturitas. 2026. Castaneda R, Tatit CP, Hurtado Andrade MD, Faubion SS, Shufelt CL.RecentReview 4. Lipoprotein(a) and Women's Cardiovascular Health: A Review. JACC. Advances. 2026. Michos ED, Saucier S, Mehran R, Koschinsky ML. 5. Lipid Metabolism in Women: A Review. Atherosclerosis. 2025. van Oortmerssen JAE, Mulder JWCM, Kavousi M, Roeters van Lennep JE.Review 6. Are Changes in Cardiovascular Disease Risk Factors in Midlife Women Due to Chronological Aging or to the Menopausal Transition?. Journal of the American College of Cardiology. 2009. Matthews KA, Crawford SL, Chae CU, et al.Observational 7. Trajectories of Lipids Around the Menopause Transition in Chinese Women: Results of the Kailuan Cohort Study. Fertility and Sterility. 2023. Dai Q, Wu S, Cao Z, et al. 8. Lipid Management in Patients With Endocrine Disorders: An Endocrine Society Clinical Practice Guideline. The Journal of Clinical Endocrinology and Metabolism. 2020. Newman CB, Blaha MJ, Boord JB, et al.Guideline 9. The Effects of Menopause Hormone Therapy on Lipid Profile in Postmenopausal Women: A Systematic Review and Meta-Analysis. Frontiers in Pharmacology. 2022. Nie G, Yang X, Wang Y, et al.SR 10. Perspectives on Dyslipidemia and Coronary Heart Disease in Women. Journal of the American College of Cardiology. 2005. Bittner V.Review 11. Dyslipidemia in Midlife Women: Approach and Considerations During the Menopausal Transition. Maturitas. 2022. Torosyan N, Visrodia P, Torbati T, Minissian MB, Shufelt CL.Review 12. Effects of gender, age and menopausal status on serum apolipoprotein concentrations.13.Lipoprotein(a).The Journal of the American Medical Association. 2025. Mora S, Kronenberg     14. Why, how and in whom should we measure levels of lipoprotein(a): A review of the latest evidence and clinical implications. Diabetes, Obesity & Metabolism. 2025. Razavi AC, Bhatia HS, Blumenthal RS, Shapiro MD, Mehta A.RecentReview 15. Red Yeast Rice for Hypercholesterolemia: JACC Focus Seminar. Journal of the American College of Cardiology. 2021. Cicero AFG, Fogacci F, Zambon A.Review 16. Overall and Sex-Specific Effect of Berberine for the Treatment of Dyslipidemia in Adults: A Systematic Review and Meta-Analysis of Randomized Placebo-Controlled Trials. Drugs. 2023. Blais JE, Huang X, Zhao JV.SR 17. Non-Genetic Influences on Lipoprotein(a) Concentrations. Atherosclerosis. 2022. Enkhmaa B, Berglund L.Review 18. NHLBI Working Group Recommendations to Reduce Lipoprotein(a)-Mediated Risk of Cardiovascular Disease and Aortic Stenosis. Journal of the American College of Cardiology. 2018. Tsimikas S, Fazio S, Ferdinand KC, et al.Review 19. Consumption of a defined, plant‐based diet reduces lipoprotein(a), inflammation, and other atherogenic lipoproteins and particles within 4 weeks. Clinical Cardiology. 2018. Najjar RS, Moore CE, Montgomery BD. 20. Lipoprotein(a): Current Evidence for a Physiologic Role and the Effects of Nutraceutical Strategies. Clinical Therapeutics. 2019. Santos HO, Kones R, Rumana U, et al.Review 21. Effect of Lipid-Lowering Therapies on Lipoprotein(a) Levels: A Comprehensive Meta-Analysis of Randomized Controlled Trials. Atherosclerosis. 2025. Xie S, Galimberti F, Olmastroni E, et al.Recent 22. Effect of Omega-3 Fatty Acid Supplementation on the Postprandial Metabolism of Apolipoprotein(a) in Familial Hypercholesterolemia. Journal of Atherosclerosis and Thrombosis. 2023. Ying Q, Croyal M, Chan DC, et al.RCT 23.Lipoprotein(a) and Cardiovascular Disease. Lancet. 2024. Nordestgaard BG, Langsted A.Review 24. Lipoprotein(a): A Genetically Determined, Causal, and Prevalent Risk Factor for Atherosclerotic Cardiovascular Disease: A Scientific Statement From the American Heart Association. Arteriosclerosis, Thrombosis, and Vascular Biology. 2022. Reyes-Soffer G, Ginsberg HN, Berglund L, et al.Guideline 25.Clinical Trial Design for Lipoprotein(a)-Lowering Therapies: JACC Focus Seminar 2/3.Journal of the American College of Cardiology. 2023. Malick WA, Goonewardena SN, Koenig W, Rosenson RS.Review 26.2026 ACC/AHA/AACVPR/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Dyslipidemia: A Report of the American Collegeof Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2026. Writing Committee Members, Blumenthal RS, Morris PB, et al.Guideline 27. Noninvasive Coronary Atherosclerotic Plaque Imaging. JACC. Cardiovascular Imaging. 2023. Kwiecinski J, Tzolos E, Williams MC, et al.Review 28. Computed Tomography Angiography Versus Agatston Score for Diagnosis of Coronary Artery Disease in Patients With Stable Chest Pain: Individual Patient Data Meta-Analysis of the International COME-CCT Consortium. European Radiology. 2022. Wieske V, Walther M, Dubourg B, et al.SR 29. Association of Coronary Artery Calcium Score With Qualitatively and Quantitatively Assessed Adverse Plaque on Coronary CT Angiography in the SCOT-HEART Trial. European Heart Journal. Cardiovascular Imaging. 2022. Osborne-Grinter M, Kwiecinski J, Doris M, et al.Clinical Trial 30. AI-Guided Quantitative Plaque Staging Predicts Long-Term Cardiovascular Outcomes in Patients at Risk for Atherosclerotic CVD. JACC. Cardiovascular Imaging. 2024. Nurmohamed NS, Bom MJ, Jukema RA, et al.Observational 31. The Lancet Commission on Rethinking Coronary Artery Disease: Moving From Ischemia to Atheroma. Lancet. 2025. Zaman S, Wasfy JH, Kapil V, et al.Review 32. Efficacy and safety of novel lipoprotein(a)‐targeted therapies: A systematic review and meta‐analysis of randomized controlled trials. Diabetes, Obesity & Metabolism. 2026. Santana AUL, Yusufzai MO, Freitas APS, et al. Recent Opinion

Dr. Antoni Chan The Weight Behind the Delay in Diagnosis: https://youtu.be/-gxaFidWRw0  Dr. Mrinalini Dey Obesity: Escalate or Reassess?: https://youtu.be/Y6f_Qt5snMI Dr. Michael Putman Managing Obesity: By PCP or Rheumatologist?: https://youtu.be/zASyKJECfiM

Explore the complex relationship between obesity, inflammation, and rheumatic disease—and how excess adiposity may influence disease development, severity, treatment response, and patient outcomes. In this expert-led discussion, leading clinicians and researchers examine how obesity can accelerate inflammatory and autoimmune rheumatic disease through metabolic, biomechanical, and immunologic pathways. The panel explores the biology of adipose tissue and its role in systemic inflammation, including how obesity affects disease risk and progression, response to rheumatologic therapies, and the potential for weight loss and other interventions to reduce inflammation and improve clinical outcomes. Expert Faculty: • Juliana Simonetti, MD • Lihi Eder, MD, PhD • Naveed Sattar, MD, PhD • Lee Kaplan, MD, PhD • Jack Cush, MD — Moderator

October is World Pet Obesity Month! We need your help in collecting pet obesity prevalence data - and you can earn $50 for your team! Visit https://www.petobesityprevention.org/2026-veterinary-clinic-pet-obesity-prevalence-survey Speaking of obesity in dogs and cats: spaying and neutering may be routine surgical procedures for most veterinary professionals and pet parents, but the nutritional shift afterward is anything but. This week, Dr. Ernie Ward and Beckie Mossor, MPA, RVT, talk with Dr. Yuki Okada, a board-certified veterinary nutritionist and Virbac's Veterinary Medicine and Nutrition Manager, about one of veterinary medicine's most useful obesity-prevention windows: What should we feed growing dogs and cats in the period surrounding spay or neuter? Dr. Yuki explains why appetite may rise while energy needs and activity fall, and why the feeding conversation should begin before surgery rather than get buried in discharge instructions. The team covers moving away from free-feeding, accounting for treat and supplement calories, measuring food with a gram scale, and giving families clear directions everyone can follow. They also unpack the clinical thinking behind Virbac VETERINARY HPM® Spayed & Neutered diets, including higher protein of animal origin to help support lean muscle, coupled with fiber for satiety. The discussion then moves beyond body weight to body condition score, muscle condition score, mobility, activity, and subtle “micro-pauses” that may signal discomfort. The takeaway: preventing unhealthy weight gain requires an early, practical plan that the entire veterinary team can reinforce. Learn more about Virbac nutrition at iVet.com, find the Association for Pet Obesity Prevention (APOP) pet-owner tools at petobesityprevention.org, and explore the World Pet Obesity Association (WPOA) clinical resources at worldpetobesity.org. #VeterinaryMedicine #VetTech #VeterinaryNutrition #PetObesity #SpayNeuter

Save 20% on all Nuzest Products WORLDWIDE with the code MIKKIPEDIA at www.nuzest.co.nz, www.nuzest.com.au or www.nuzest.comCurranz Supplement: Use code MIKKIPEDIA to get 20% off your first order - go to www.curranz.co.nz  or www.curranz.co.uk to order yours NZ listeners - save 10% off Calocurb by using the code Mikkipedia10 at www.calocurb.co.nzEpisode SummaryThis week Mikki talks with Dr Robert Kushner, an obesity medicine physician, educator and researcher with over four decades in the field. He is Professor Emeritus at Northwestern University Feinberg School of Medicine, a founder and the first chair of the American Board of Obesity Medicine, and a past president of The Obesity Society. He was also the corresponding author on the STEP 1 semaglutide trial published in the New England Journal of Medicine in 2021, and sat on the steering committee for SELECT — so he has watched this field from the inside, before and after GLP-1 receptor agonists arrived.The conversation traces what clinicians actually understood about obesity in the 1980s and 90s, Bob's own leptin trial and why it did not deliver, and how reframing obesity as a biological disease led researchers to the gut hormones. From there it moves into the practical territory: how the clinical conversation has shifted from counting calories to diet quality, which side effects are real and which are social media noise, what happens to muscle mass and physical function, how dose escalation should actually work, why hunger returning is not the same as weight regain, and what the evidence says about stopping. Bob is careful throughout to separate what the trials show from what is still unknown, which makes this a useful listen whether you work with clients on these medications or are weighing them up yourself.Key TopicsWhat clinicians believed about obesity three decades ago — excess body fat was known to cause system-wide harm, but the mechanisms, and appetite dysregulation in particular, were not understood, and weight regain after lifestyle intervention was already expectedBob's own leptin trial in the 1990s, published in JAMA, and why leptin turned out to be a useful biological signal rather than a treatment — it defends against weight loss but was never built to stop overeatingThe STEP 1 result and why it changed the field: 15% average weight loss at 68 weeks against a previous benchmark of 6–9%, with a third of participants losing 20%How the clinical conversation shifted from quantity to quality — when the medication does the heavy lifting, the questions become whether someone is eating enough, staying hydrated and getting sufficient protein, rather than how to control cravingsWhich side effects are real and which are overstated: GI effects are the genuine shared profile and can be substantially reduced through diet during dose escalation, while hair thinning and facial fat loss follow large weight loss by any routeMuscle mass, sarcopenia and the groups who need watching, alongside the consistent finding that physical function and quality of life improve in trials — possibly because fatty infiltration of muscle resolvesDose escalation in the real world versus the trial protocol, and why there are still no pretreatment predictors of who will respondWhy appetite drifting back is normal and not a failure — Bob's framing of restored appetite regulation at a lower body weight, with "the amplitude smaller than it was before"Benefits beyond weight loss, including SELECT's 20% reduction in cardiovascular events on top of standard care, plus sleep apnoea, knee osteoarthritis, MASH and psoriasis — driven both by weight loss and by independent mechanismsCost and access, microdosing, extending the interval between injections, and where bariatric surgery still fitsChapters00:00 Introduction05:13 Obesity medicine before GLP-1s13:34 Gut hormones and the STEP 1 result21:00 From calorie counting to diet quality25:00 Side effects and social media myths29:54 Muscle mass, function and exercise35:08 Dose escalation and who responds40:30 When hunger comes back46:37 Stopping the drug, cost and access52:24 Benefits beyond weight loss57:37 Long-term safety and microdosing1:01:10 Coming off, surgery and what's nextGuest / ResourcesDr Robert KushnerProfessor Emeritus, Northwestern University Feinberg School of MedicineFounder and first chair of the American Board of Obesity MedicinePast president of The Obesity SocietyAuthor or editor of 15 books, 56 book chapters and 230 original and review articlesWebsite: drrobertkushner.comBooksSix Factors to Fit: Weight Loss that Works for You! — written for the patientPatient-Centered Weight Management: The Six Factor Professional Program and Toolkit — written for the clinicianTrials and studies discussedSTEP 1 — once-weekly subcutaneous semaglutide, New England Journal of Medicine, 2021. 1,961 adults, 68 weeks, ~15% average weight loss. Bob was the corresponding authorSTEP 1 extension — the off-treatment follow-up showing weight regain after stoppingSELECT — semaglutide versus placebo in 17,000 people with obesity or overweight and pre-existing cardiovascular disease but no diabetes, over nearly four years. A 20% reduction in second heart attack, stroke or cardiovascular death, on top of standard care. Bob sat on the steering committeeSURMOUNT-1 extension — participants with pre-diabetes maintained on treatment for three years, with weight remaining stableLook AHEAD — an intensive behavioural therapy trial in diabetes; of those who lost 10% of body weight, around 40% maintained it for about four years without medicationKushner's leptin trial (1990s) — placebo versus leptin injections, published in JAMAA tirzepatide dose-reduction study — 15mg reduced to 5mg, with partial weight regainA randomised microdosing study in people with diabetes — standard monthly dose escalation versus gradual weekly escalation to the same final dose, showing better tolerability and fewer dropouts. Bob refers to this study but does not name it, so it is referred-to-but-not-identifiedResearchers mentionedAndres Acosta, Mayo Clinic — phenotype and biomarker work on predicting treatment responseOrganisationsNorthwestern University Feinberg School of MedicineAmerican Board of Obesity MedicineThe Obesity SocietyObesity Action CoalitionNovo Nordisk — the sponsor of STEP 1Mayo ClinicMedications and hormones discussed GLP-1 receptor agonists; semaglutide; liraglutide; tirzepatide; phentermine; topiramate; naltrexone; bupropion. Gut hormones: GLP-1, GIP, glucagon, amylin. Also leptin, insulin, statins, beta blockers, testosterone and oestrogen.Terms that come up Appetite dysregulation; food noise; leptin resistance; medu...

Credits: 0.25 AMA PRA Category 1 Credit™   CME/CE Information and Claim Credit: https://www.pri-med.com/online-education/podcast/frankly-speaking-cme-502 Overview: Abdominal obesity can influence both the severity of menopausal symptoms and treatment decisions. Listen in as we discuss how to recognize this important relationship, apply practical screening tools, and individualize menopause management to improve symptom control and overall health outcomes for your patients. Episode resource links: Wang, D. , Wang, F. , Zheng, J. , Chen, X. , Lei, Y. & Su, J.  (9900).  Menopausal symptom network differences between women with and without waist-to-height ratio-defined abdominal obesity.  Menopause,  Publish Ahead of Print , doi: 10.1097/GME.0000000000002794. Managing Menopausal Symptoms: Common Questions and Answers. Chang JG, Lewis MN, Wertz MC. American Family Physician. 2023;108(1):28-39. Guest: Jillian Joseph, MPAS, PA-C   Music Credit: Matthew Bugos Thoughts? Suggestions? Email us at FranklySpeaking@pri-med.com  The views expressed in this podcast are those of Dr. Domino and his guests and do not necessarily reflect the views of Pri-Med.

Welcome to the latest episode (September 2026) of DOC Updates, where every month Neil Skolnik, MD and John Russell, MD review the most important articles on diabetes, obesity, and cardiometabolic disease. This month on DOC Updates: Diaz KM, Murdock ME, Serafini MA, et al. Evaluating movement breaks as a public health strategy to mitigate the harms of prolonged sitting: a large-scale pragmatic intervention. British Journal of Sports Medicine 2026;60:1208-1217. Chorniy, et al. Progression to Diabetes by Adults With Prediabetes Who Use the National Diabetes Prevention Program: A Natural Experiment. Diabetes Care 20 August 2026; 49 (9): 1576–1584. doi.org/10.2337/dc25-2485 Harnois-Leblanc, et al. Genetic Determinants of Macronutrient Intake Are Associated With Specific Food Intake in Youth: A Cohort Study Across Childhood and Adolescence. Diabetes Care 20 August 2026; 49 (9): 1645–1653. doi.org/10.2337/dc25-2975 Guan, et al. Sarcopenic Obesity and Risk of Incident Type 2 Diabetes: A Prospective Cohort Study and Landmark Analysis From the UK Biobank. Diabetes Care 20 August 2026; 49 (9): 1663–1668. doi.org/10.2337/dc26-0797 Guo, et al. Life Course Cumulative BMI Burden From Childhood to Adulthood and Risk of Metabolic Multimorbidity: A 36-Year Prospective Cohort Study. Diabetes Care 20 August 2026; 49 (9): 1567–1575. doi.org/10.2337/dc25-2889 Presented by: Neil Skolnik, MD, Professor of Family and Community Medicine, Sidney Kimmel Medical College, Thomas Jefferson University; Associate Director, Family Medicine Residency Program, Abington Jefferson Health John J. Russell, MD, Professor of Family and Community Medicine, Sidney Kimmel Medical College, Thomas Jefferson University; Chair-Department of Family Medicine, Abington Jefferson Health DOC Updates is a monthly podcast that presents and discusses the latest clinically relevant articles from the American Diabetes Association's three science and medical journals—Diabetes, Diabetes Care, and Diabetes, Obesity, and CardioMetabolic CARE. Intended for practicing physicians and health care professionals, DOC Updates discusses how the latest research is relevant in clinical practice. For information about the American Diabetes Association's scholarly journals, visit diabetesjournals.org. For more about this podcast, click here.

You're taking a GLP-1 medication, but the scale isn't moving the way you expected. Maybe you've even watched someone else say they lost 20 pounds in two months and wondered, "Why isn't this working for me?" If you've been asking yourself that question, I want you to know that your experience with a GLP-1 medication may look very different from someone else's. In this episode, I'm breaking down four reasons you may not be losing as much weight as you expected on a GLP-1, and what I look at when a patient tells me their medication isn't working. I'll also talk about something that can easily get lost when we compare our weight loss journey to what we see on social media. Before you decide that your GLP-1 has failed, there are some important questions to consider. Your dose, your overall health habits, your nutrition, and your treatment plan can all be part of the bigger picture. If you're frustrated by slow weight loss on a GLP-1, listen to this episode before you assume you're doing something wrong. Episode Highlights: Why your weight loss may not look like someone else's, even when you're taking the same type of medication What I look at when a patient feels their GLP-1 isn't working When your dose may be part of the picture Why nutrition and lifestyle still matter during GLP-1 treatment A question you may not expect to ask when your appetite has changed When it may be time to reassess your treatment plan Why comparing your progress to someone on social media can be misleading The mindset I want you to have when your weight loss isn't moving as quickly as you hoped Connect with Dr. Alicia Shelly Website | drshellymd.com Facebook | www.facebook.com/drshellymd Instagram | @drshellymd Linked In | www.linkedin.com/in/drshellymd Twitter | @drshellymd About Dr. Alicia Shelly Dr. Alicia Shelly was raised in Atlanta, GA. She received her Doctorate of Medicine from Case Western Reserve University School of Medicine in Cleveland, OH.  Dr. Shelly has been practicing Primary Care and Obesity medicine since 2014.  In 2017, she became a Diplomat of the American Board of Obesity Medicine. She is the lead physician at the Wellstar Medical Center Douglasville. She started a weekly podcast & Youtube channel entitled Back on Track: Achieving Healthy Weight loss,  where she discusses how to get on track and stay on track with your weight loss journey. She has spoken for numerous local and national organizations, including the Obesity Medicine Association, and the Georgia Chapter of the American Society of Metabolic and Bariatric Surgeons. She has been featured on CNN, Fox 5 News, Bruce St. James Radio show, Upscale magazine, and Shape.com. She was named an honoree of the 2021 Atlanta Business Chronicle's 40 under 40 award. She also is a collaborating author for the, "Made for More: Physician Entrepreneurs who Live Life and Practice Medicine on their own terms''. Resources: FREE! Discover the 5 Reasons Your Weight-Loss Journey Has Gotten Derailed (And How To Get Back On Track!)

Male fertility is responsible for up to half of all fertility challenges, yet it often receives far less attention than female fertility. In this episode, Dr. Lorne Brown welcomes board-certified urologist and reproductive health expert Dr. Mark Ratner for an evidence-based discussion on sperm health, fertility testing, DNA fragmentation, lifestyle factors, and the latest research on supplements that may support male reproductive health.Together, they explore why every fertility evaluation should include the male partner, what a semen analysis can—and cannot—tell you, when advanced testing becomes valuable, and how obesity, testosterone therapy, medications, heat exposure, and nutrition can influence sperm quality. Whether you're trying to conceive naturally or through IVF, this conversation offers practical insights for both patients and practitioners.Key Takeaways:Male factors contribute to approximately 50% of infertility cases, making male evaluation essential.A single semen analysis isn't enough—results can vary, so two tests performed a few weeks apart provide a more accurate assessment.DNA fragmentation testing can be valuable after recurrent IVF failure or in selected clinical situations, but it is not a universal screening test.Obesity and testosterone replacement therapy are two of the most common reversible factors that negatively affect sperm production.Lifestyle, nutrition, antioxidants, and targeted supplements may improve sperm health, particularly DNA integrity and motility.Where to find Dr. Mark Ratner:Website: https://theralogix.com/Special Offer: https://theralogix.com/discount/LORNE?redirect=/products/ovanad Ian Kent - VP, Sales & Business Development

To have your question featured in a future video, please visit: DrMorses.TV/ask Buy herbs: https://jo.my/handcrafted-formulas Getting Started Guide: https://jo.my/start-here-hbf

Welcome to the latest Midlife Minute. Today, I'm answering listeners' questions about cardiovascular risk, focusing on Lp(a), LDL, statins, and the changes women experience after menopause. Stay tuned for more! IN THIS EPISODE, YOU WILL LEARN: Why women should have their Lp(a) checked both before and after menopause How Lp(a) works as a risk enhancer, and how cardiovascular risk becomes more significant when elevated Lp(a) occurs alongside high LDL Why family history is particularly helpful for women with a 10-year calculated cardiovascular risk that looks reassuringly low I review the current guidelines for primary prevention Why, even though research has shown reductions in major cardiac events with GLP-1s, GLP-1s do not replace statins for lowering LDL  What a CAC score can reveal about coronary artery calcification, and what it cannot detect How AI-assisted CT angiography (such as Clearly) can map, quantify, and characterize plaque throughout the coronary branches Connect with Cynthia Thurlow   Follow on X, Instagram & LinkedIn Check out Cynthia's website. Submit your questions to support@cynthiathurlow.com  Join other like-minded women in a supportive, nurturing community: The Midlife Pause/Cynthia Thurlow.  Purchase Cynthia's book, The Menopause Gut. Cynthia's Intermittent Fasting Transformation Book The Midlife Pause Supplement Line References: 1.  ​Lipoprotein(a) and Women's Cardiovascular Health: A Review. JACC. Advances. 2026. Michos ED, Saucier S, Mehran R, Koschinsky ML.Recent 2.  ​Sex Differences of Lipoprotein(a) Levels and Associated Risk of Morbidity and Mortality by Age: The Copenhagen General Population Study. Atherosclerosis. 2022. Simony SB, Mortensen MB, Langsted A, et al. 3. Managing Atherosclerotic Cardiovascular Risk in Young Adults: JACC State-of-the-Art Review. Journal of the American College of Cardiology. 2022. Stone NJ, Smith SC, Orringer CE, et al.Review 4. Thirty-Year Risk of Cardiovascular Disease Among Healthy Women According to Clinical Thresholds of Lipoprotein(a). JAMA Cardiology. 2026. Nordestgaard AT, Chasman DI, Moorthy V, et al.RecentObservational 5.  ​Lipoprotein(a).The Journal of the American Medical Association. 2025. Mora S, Kronenberg  6. Clinical Practice Guideline on Lipid Management for Cardiovascular Disease Risk Reduction. Department of Veterans Affairs (2026). 2026. Paul Heidenreich, Lance Spacek, Neil Gregor, et al. Guideline 7. Lipoprotein(a) and Family History Predict Cardiovascular Disease Risk. Journal of the American College of Cardiology. 2020. Mehta A, Virani SS, Ayers CR, et al.Observational 8. 2010 ACCF/AHA Guideline for Assessment of Cardiovascular Risk in Asymptomatic Adults: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Journal of the American College of Cardiology. 2010. Greenland P, Alpert JS, Beller GA, et al.Guideline 9. Prevalence and Prognostic Implications of Coronary Artery Calcification in Low-Risk Women. The Journal of the American Medical Association. 2016. Kavousi M, Desai CS, Ayers C, et al.SR 10. ​Coronary Artery Calcium Scores and Risk for Cardiovascular Events in Women Classified as “Low Risk” Based on Framingham Risk Score: The Multi-Ethnic Study of Atherosclerosis (MESA). Archives of Internal Medicine. 2007. Lakoski SG, Greenland P, Wong ND, et al.Observational 11. 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Journal of the American College of Cardiology. 2019. Arnett DK, Blumenthal RS, Albert MA, et al.Guideline 12. HOPE for Rational Statin Allocation for Primary Prevention: A Coronary Artery Calcium Picture Is Worth 1000 Words. Mayo Clinic Proceedings. 2020. Orringer CE, Maki KC.Review 13. Summary of Updated Recommendations for Primary Prevention of Cardiovascular Disease in Women: JACC State-of-the-Art Review. Journal of the American College of Cardiology. 2020. Cho L, Davis M, Elgendy I, et al.Review 14. Health Maintenance in Postmenopausal Women. American Family Physician. 2025. Plesa M, Wong A, Katsaggelos E.Guideline 15.  ​Semaglutide and Cardiovascular Outcomes by Baseline HbA1c and Change in HbA1c in People With Overweight or Obesity but Without Diabetes in SELECT. Diabetes Care. 2024. Lingvay I, Deanfield J, Kahn SE, et al.RCT 16.  ​Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. The New England Journal of Medicine. 2023. Lincoff AM, Brown-Frandsen K, Colhoun HM, et al.RCT 17. Long-Term Weight Loss Effects of Semaglutide in Obesity Without Diabetes in the SELECT Trial. Nature Medicine. 2024. Ryan DH, Lingvay I, Deanfield J, et al.RCT 18. Interventions for the Prevention and Management of Cardiometabolic Multiple Long-Term Conditions. Lancet. 2026. Valabhji J, Hope D, Sayed NE, et al.RecentReview 19. Glucagon‐Like Peptide‐1 Receptor Agonists and Major Adverse Cardiovascular Events in Patients With and Without Diabetes: A Meta‐Analysis of Randomized‐Controlled Trials. Clinical Cardiology. 2024. Hosseinpour A, Sood A, Kamalpour J, et al.SR 20. ​FDA Orange Book. FDA Orange Book. 2026. 21. 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes-2026. Diabetes Care. 2026. American Diabetes Association Professional Practice Committee for Diabetes*.RecentGuideline 22. Premature Coronary Artery Disease in Women: Sex-Specific Risk Factors, Pathogenetic Mechanisms and Clinical Implications. Annals of Medicine. 2026. Li F, Hong D, Yang M, et al.RecentReview 23. Cardiovascular Disease Risk Factors in Women: The Impact of Race and Ethnicity: A Scientific Statement From the American Heart Association. Circulation. 2023. Mehta LS, Velarde GP, Lewey J, et al.Guideline 24. Preventing CVD in Women: Common Questions and Answers. American Family Physician. 2023. Westfall E, Viere AB, Genewick JE.Review 25. Menopause Transition and Cardiovascular Disease Risk: Implications for Timing of Early Prevention: A Scientific Statement From the American Heart Association. Circulation. 2020. El Khoudary SR, Aggarwal B, Beckie TM, et al.Guideline

In this School of Doza Health Tech Series episode, Nurse Doza breaks down Hume Health—the at-home body scan he keeps in his kitchen, his bathroom, and his clinic. He explains why a single weight reading hides at least four things moving in different directions, why visceral fat is the compartment a standard scale is blind to, and how a three-to-five-second barefoot reading turns diet, training, and sleep changes into a trend line you can actually act on. If you've changed your habits and have no idea whether any of it worked, this is the missing feedback loop. FEATURED PARTNER The Hume Pod is the at-home body scan Nurse Doza uses every morning. Step on it barefoot and in three to five seconds it returns estimates for body fat, muscle mass, bone mass, and visceral fat, alongside heart rate, basal metabolic rate, and a calculated body-age score—all synced to a free app that charts the trend over weeks and months instead of handing you one number a day. That's exactly the problem this episode is about: weight alone can't tell you what changed, and the compartments that matter most for metabolic health are the ones a normal scale never shows you. Hume backs the device with a 10-year warranty.

Next time you look at the calories on the back of a packet or the nutritional breakdown of a recipe, remember that number doesn't tell you the whole story. It says nothing about the nutrients, the quality of the food, how satisfying it'll be, or even how many calories your body will actually absorb.To unpack it all, I'm joined by Professor Giles Yeo, Professor of Molecular Neuroendocrinology at the University of Cambridge, MBE, and author of the brilliant book Why Calories Don't Count.We cover:5 reasons calorie counting matters less than we thinkWhy "low-cal" doesn't always mean healthyWhy we don't absorb every calorie we eatWhy the calories in nuts, avocados and seeds aren't the same as the calories in a ultra-processed foods, even when the numbers matchIs fruit juice really healthy?3 strategies to maintain a healthy weightI hope this changes the way you think about calories and gives you a few practical ideas you can start using straight away. If you know someone who's always checking the calorie label before anything else, send this episode their way.As always, thanks for listening!Dr Rupy xMore from Professor Giles Yeohttps://www.wolfson.cam.ac.uk/people/giles-yeohttps://x.com/GilesYeohttps://www.instagram.com/gilesyeo/?hl=enMore from us

The Obesity Journal Club explores the TOGETHER PsA and STEP 9 trials and what emerging evidence tells us about the relationship between obesity, weight loss, and rheumatic disease. Authors of the papers and experts will discuss the results of these trials, discuss how we consider obesity as both a comorbidity and part of the disease course, and share practical strategies for addressing obesity in everyday rheumatology practice. Speakers: Dr. Philip Mease Dr. Tom Appleton Dr. Jack Cush (moderator)

Raised my nephew for much of my teens (my sister, 10 years older, lived at home).  I was a surrogate parent before I was even an adult myself.That early taste of "parenthood" left me terrified to have my own kids until I met my husband and knew it would be different.I came off birth control to start trying, and irregular periods confirmed what I'd long suspected: PCOS.I worked with my OB and a fertility team for both pregnancies in awe of how precisely they manage the endocrine system.That struggle inspired additional learning: became Obesity Medicine certified to understand the hormone-weight connection.Realized women hit the same wall at menopause so pursued Menopause Society certification too.Founded Achieve Health NV in Reno so patients get real time and a real ear because they are hard and impact people profoundly.Both my boys were very content where they were. My first arrived at 41 weeks after two failed induction attempts and a c-section, my second was a planned c-section because my cervix was more secure than Fort Knox.Now they're two wonderfully glam little guys who love nothing more than belting out a song.I am the co-Founder of Achieve Health NV which is a membership based clinic in Reno, NV offering primary care and weight management services.FIND HER HERE:www.achievehealthnv.com; www.facebook.com/achievehealthnv.; www.instagram.com/achievehealthnv

Brain Health Reset: 9 Weeks to Better Energy, Focus & Sleephttps://rawfoodmealplanner.kit.com/549de1dbb2 Join January 2027 RawFoodMealPlanner's 21-Day Challengehttps://rawfoodhealthempowermentsummit.com/the-rawfoodmealplanner-s-21-day-new-year-meal-prep-challenge Boost Your Wellness Journey:The Brain Reboot Plan: 5 Simple Daily Shifts for More Focus, Energy & Peacehttps://rawfoodmealplanner.com/brain-reboot-plan/Revitalize Your Brain: A Lifestyle Approach for Women Over 50https://rawfoodmealplanner.clickfunnels.com/webinar-replay-brain-health-breakthrough-coaching-programRESET: 3 Metabolic Mistakes Women 30+ Make And How to Fix Themhttps://rawfoodmealplanner.com/reset-3-metabolic-mistakes-women-30-make-and-how-to-fix-them/The Lancet published a study here https://www.thelancet.com/journals/lanhl/article/PIIS2666-7568(24)00191-0/fulltext emphasizing that young adults (ages 18–39) are a neglected but crucial window for dementia prevention. Most dementia research focuses on mid-to-late life, yet many modifiable risk factors that affect long-term brain health emerge or peak in young adulthood.Key Modifiable Risk FactorsEducation: Low levels reduce cognitive reserve and increase the risk of dementia.Hearing loss: One billion young adults globally are at risk due to unsafe listening practices.Traumatic brain injury (TBI): High rates from sports, motor accidents, and intimate partner violence.Hypertension: One in 12 young adults is affected; rates higher among Black Americans and in LMICs.Alcohol use: Peaks in early 20s, linked to long-term brain changes.Obesity & physical inactivity: Both rising rapidly; linked to inflammation and cardiovascular risk.Smoking/vaping: 90% of daily smokers start before 26.Depression & social isolation: Peak in early 20s, linked to later ADRD (Alzheimer's disease and related dementias) risk.Diabetes: 4% prevalence in young adults; prediabetes affects 1 in 4.Environmental factors: Air pollution, vision loss, high LDL cholesterol, and even emerging risks like sleep disruption, stress, spirituality, and microplastics.Join the Conversation:Subscribe and share this episode with anyone on their own path of health and transformation. // HOST Samantha Salmon, NBC-HWC Nationally Board Certified Health & Wellness Coach Brain Health Licensed Trainer | Integrative Nutrition Coach | Intuitive Nutrition Coach for Brain & Metabolic HealthThe information provided in this broadcast is for educational purposes only and is not intended as medical advice. These statements have not been evaluated by the Food and Drug Administration or the equivalent in your country. Any products/services mentioned are not intended to diagnose, treat, cure, or prevent disease. RawFoodMealPlanner.com © 2026

Discover how emerging targeted therapies address systemic drivers in MASLD and MASH. Credit available for this activity expires: 9/8/27 Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/targeting-metabolic-driver-forward-looking-approach-obesity-2026a1000t0l?ecd=bdc_podcast_libsyn_mscpedu

Ver um telejornal está cada vez mais difícil: crise climática, negacionismo, ódio, racismo, misoginia, homofobia, preconceitos em geral... Pessoas conscientes quase sempre se revoltam com isso. Tem como se manter informado sem ter um piripaque?Confira o papo entre o leigo curioso, Ken Fujioka, e o cientista PhD, Altay de Souza.>> OUÇA (51min 47s)*SOBRE O NARUHODONaruhodo! (@naruhodopodcast) é o podcast pra quem tem fome de aprender. Ciência, senso comum, curiosidades, desafios e muito mais. Com o leigo curioso, Ken Fujioka (@kenfujioka), e o cientista PhD, Altay de Souza (@altayals).Edição: Reginaldo Cursino (@reginaldocursino)Ilustração e Capa: Felipe Cruz (@felipecruzart)http://naruhodo.b9.com.br*REFERÊNCIASMen, Women and Social Connectionshttps://www.pewresearch.org/social-trends/2025/01/16/men-women-and-social-connections/May 2021 American Perspectives Surveyhttps://www.americansurveycenter.org/download/may-2021-american-perspectives-survey/Dealing with information overload: a comprehensive reviewhttps://www.frontiersin.org/journals/psychology/articles/10.3389/fpsyg.2023.1122200/fullStrategies for managing information overload: a systematic reviewhttps://www.emerald.com/jd/article-abstract/82/2/249/1332007/Strategies-for-managing-information-overload-aStop Fiddling With Your Phone and Go Offline: People Experiencing High Information Overload Have Sparse Online Sessionshttps://dl.acm.org/doi/full/10.1145/3772318.3790822Modeling Information Anxietyhttps://scholarworks.sjsu.edu/libphilprac/2758/Assessing the relationship between information overload, role stress, and teachers' job performance: Exploring the moderating effect of self-efficacyhttps://journals.sagepub.com/doi/abs/10.1177/02666669241232422Slow Death (Sovereignty, Obesity, Lateral Agency)https://www.journals.uchicago.edu/doi/10.1086/521568Understanding Price Formation through a Boid-Based Analysis: Insights from Thailand in the Context of Emerging Economies https://ir.ide.go.jp/record/2001524/files/IDP000975_001.pdfNecropolitics https://web.archive.org/web/20151010043651/https://www.dartmouth.edu/~lhc/docs/achillembembe.pdfNASCIMENTO DA BIOPOLÍTICAhttps://digitecavfx.pt/index.php?page=13&id=355&db=American Civil War https://www.britannica.com/event/American-Civil-WarCultural Revolution https://www.britannica.com/event/Cultural-RevolutionWriting Value in a Neoliberal World: Necropolitics and Affective Rhetorichttps://link.springer.com/chapter/10.1057/9781137547774_1Spatial ecology: Its effects on the choice of friends and enemieshttps://www.sciencedirect.com/science/article/abs/pii/0022103176900305Naruhodo #467 - Como tomar decisões sob pressão? https://www.youtube.com/watch?v=q12bkQ1-o5ENaruhodo #333 - Quais as consequências do excesso de reuniões virtuais?https://www.youtube.com/watch?v=XMQdUfCWKEkNaruhodo #414 - A educação científica salvará o mundo? https://www.youtube.com/watch?v=OLaBswwX9yMNaruhodo #39 - A ignorância é uma benção? https://www.youtube.com/watch?v=MIKhzU6VNy8Naruhodo #357 - Existe possibilidade de consenso na polarização? https://www.youtube.com/watch?v=KhyKRnhjnbwNaruhodo #336 - Podemos confiar nas pesquisas eleitorais? - Parte 1 de 2https://www.youtube.com/watch?v=6pdBfd6RoboNaruhodo #337 - Podemos confiar nas pesquisas eleitorais? - Parte 2 de 2 https://www.youtube.com/watch?v=VxtAD9gINSQNaruhodo #267 - O que é dissonância cognitiva? https://www.youtube.com/watch?v=1xJwqmir5UwNaruhodo #268 - O que é dissonância cognitiva? - Parte 2 de 2 https://www.youtube.com/watch?v=--OHlHmOQTMNaruhodo #453 - Existe racismo reverso?https://www.youtube.com/watch?v=j2v4E7GWX7MNaruhodo #436 - A violência faz parte da "natureza humana"? https://www.youtube.com/watch?v=AnjRI8sfTJQNaruhodo #348 - Sentir medo e ansiedade é algo ruim? https://www.youtube.com/watch?v=u30dN7ACvE4Naruhodo #312 - Ficar sentado muito tempo aumenta a chance de morrer mais cedo?https://www.youtube.com/watch?v=6ZFLoDFLFTYNaruhodo #346 - Programação Neurolinguística (PNL) tem base científica? - Parte 1 de 2 https://www.youtube.com/watch?v=p9-iauANzY0Naruhodo #347 - Programação Neurolinguística (PNL) tem base científica? - Parte 2 de 2 https://www.youtube.com/watch?v=yggQXOE9lRYNaruhodo #285 - Por que outras pessoas não entendem coisas que são óbvias para nós?https://www.youtube.com/watch?v=sG51qICc-ewNaruhodo #469 - Temos livre arbítrio? - Parte 1 de 2 https://www.youtube.com/watch?v=nwPwrLeZrRANaruhodo #470 - Temos livre arbítrio? - Parte 2 de 2 https://www.youtube.com/watch?v=rPnl-FJrVbsNaruhodo #429 - Qual o impacto das bets em nossas vidas? https://www.youtube.com/watch?v=g8lC8YEJRcQ*APOIE O NARUHODO!O Altay e eu temos duas mensagens pra você.A primeira é: muito, muito obrigado pela sua audiência. Sem ela, o Naruhodo sequer teria sentido de existir. Você nos ajuda demais não só quando ouve, mas também quando espalha episódios para familiares, amigos - e, por que não?, inimigos.A segunda mensagem é: existe uma outra forma de apoiar o Naruhodo, a ciência e o pensamento científico - apoiando financeiramente o nosso projeto de podcast semanal independente, que só descansa no recesso do fim de ano.Manter o Naruhodo tem custos e despesas: servidores, domínio, pesquisa, produção, edição, atendimento, tempo... Enfim, muitas coisas para cobrir - e, algumas delas, em dólar.A gente sabe que nem todo mundo pode apoiar financeiramente. E tá tudo bem. Tente mandar um episódio para alguém que você conhece e acha que vai gostar.A gente sabe que alguns podem, mas não mensalmente. E tá tudo bem também. Você pode apoiar quando puder e cancelar quando quiser.O apoio mínimo é de 15 reais e pode ser feito pela plataforma ORELO ou pela plataforma APOIA-SE. Para quem está fora do Brasil, temos até a plataforma PATREON.É isso, gente. Estamos enfrentando um momento importante e você pode ajudar a combater o negacionismo e manter a chama da ciência acesa. Então, fica aqui o nosso convite: apóie o Naruhodo como puder.bit.ly/naruhodo-no-orelo

New study attempts to resolve question over which has contributed more to our current obesity epidemic—diet or sedentary lifestyle? Pros/cons of CT scans vs. MRIs for investigating abdominal complaints; Fish oil rivals effectiveness of antibiotics for periodontal disease; The MIND diet vs. KetoFLEX Diet for fending off cognitive decline; Vitamin B3 helps relieve Raynaud's symptoms; After American Heart Association green lights coffee, new study shows high consumption can accelerate bone loss; High-dose vitamin D protects memory in light sleepers.

Have you ever wondered whether compounded GLP-1 medications are as safe and effective as brand-name medications? Or how you can tell if a GLP-1 or peptide product is fake? In this episode of Back on Track: Achieving Healthy Weight Loss, I'm continuing my Ask the Obesity Doctor series, where I answer real questions you've left on my YouTube videos and social media. This time, I'm talking about safety. I'll answer five questions about compounded GLP-1 medications, counterfeit and black-market products, medication interactions, side effects, and something I hear frequently from patients: "Ozempic face." I'll explain the difference between brand-name and compounded medications and why compounded medications have not gone through the same rigorous testing as brand-name medications. I'll also talk about why you can't reliably tell whether a GLP-1 or peptide product purchased from the black market is authentic or counterfeit. I'll discuss medication combinations that require extra caution when taking GLP-1 medications, including oral birth control and warfarin, and what you should do if you experience symptoms that concern you. Finally, I'll explain what people mean when they talk about "Ozempic face," why it doesn't happen to everyone, and why you shouldn't assume your experience with a GLP-1 medication will be the same as someone else's. These are questions I hear frequently, and my goal is to help you better understand what to discuss with your own healthcare provider. This episode is for education only and is not a substitute for personalized medical advice. Episode Highlights: The difference between brand-name and compounded GLP-1 medications Why compounded medications have not gone through the same rigorous testing as brand-name medications Why you cannot reliably tell if a black-market GLP-1 or peptide product is authentic Why I recommend avoiding counterfeit and black-market peptide products Medication combinations that require extra caution when taking GLP-1 medications What to do if you experience unusual or concerning side effects What "Ozempic face" actually means and why it doesn't happen to everyone Why you should not compare your GLP-1 experience to someone else's If you haven't listened to Part 1 yet, I recommend starting there and then continuing with this episode for the second set of questions. Listen to Part 1: #254: Ask the Obesity Doctor Part 1: GLP-1, Contrave, Thyroid, Dosing & Calories https://bit.ly/BackOnTrackEpisodes  If you're using a GLP-1 medication, considering one, or simply trying to understand the information you're seeing online, I hope this episode helps you have a more informed conversation with your healthcare provider.   Connect with Dr. Alicia Shelly Website | drshellymd.com Facebook | www.facebook.com/drshellymd Instagram | @drshellymd Linked In | www.linkedin.com/in/drshellymd Twitter | @drshellymd   About Dr. Alicia Shelly Dr. Alicia Shelly was raised in Atlanta, GA. She received her Doctorate of Medicine from Case Western Reserve University School of Medicine in Cleveland, OH.  Dr. Shelly has been practicing Primary Care and Obesity medicine since 2014.  In 2017, she became a Diplomat of the American Board of Obesity Medicine. She is the lead physician at the Wellstar Medical Center Douglasville. She started a weekly podcast & Youtube channel entitled Back on Track: Achieving Healthy Weight loss,  where she discusses how to get on track and stay on track with your weight loss journey. She has spoken for numerous local and national organizations, including the Obesity Medicine Association, and the Georgia Chapter of the American Society of Metabolic and Bariatric Surgeons. She has been featured on CNN, Fox 5 News, Bruce St. James Radio show, Upscale magazine, and Shape.com. She was named an honoree of the 2021 Atlanta Business Chronicle's 40 under 40 award. She also is a collaborating author for the, "Made for More: Physician Entrepreneurs who Live Life and Practice Medicine on their own terms''. Resources: FREE! Discover the 5 Reasons Your Weight-Loss Journey Has Gotten Derailed (And How To Get Back On Track!)

Dr. Jack Cush reviews the news and journal articles from the past week on RheumNow.com.  New drugs approved, new drugs halted and some drugs out of control.

Credits: 0.75 AMA PRA Category 1 Credit™   CME/CE Information and Claim Credit: https://www.pri-med.com/online-education/podcast/frankly-speaking-cme-500 Overview: To celebrate our 500th episode, each member of our team revisits a popular topic from the podcast's earlier installments—GLP-1s, cervical and breast cancer screening, diet and exercise, contraception, hypertension, and lipid management—to trace how the evidence and guidelines have changed since it was first covered. Whether you're catching up or reinforcing what you know, this milestone episode helps you bring the latest evidence into everyday patient care. Guest: Robert Baldor, MD, Alan Ehrlich, MD, Susan Feeney, DNP, FNP-BC; FAANP, Jillian Joseph, PA, Mariyan L. Montaque, DNP, FNP-BC, Jill Terrien PhD, ANP-BC, FAAN   Music Credit: Matthew Bugos Thoughts? Suggestions? Email us at FranklySpeaking@pri-med.com  Episode resource links:  Zhou H et al.  Evaluation and Comparison of the PREVENT and Pooled Cohort Equations for 10‐Year Atherosclerotic Cardiovascular Risk Prediction. Journal of the American Heart Association Volume 14, Number 4 Goff DC et al. 2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association task force on practice guidelines. Circulation. 2014;129:S49–S73. Circulation. 2018 Jul 24;138(4):345-355.  eClinicalMedicine 2025: 103741. Curry, J. (2018). Screening for cervical cancer: US Preventive Services Task Force Recommendation Statement. JAMA.320(7):674-686. doi:10.1001/jama.2018.10897 https://www.ncbi.nlm.nih.gov/pubmed/30140884  Perkins RB, Wolf AMD, Church TR, et al. Self-collected vaginal specimens for human papillomavirus testing and guidance on screening exit: An update to the American Cancer Society cervical cancer screening guideline. CA Cancer J Clin. 2026;e70041. doi:10.3322/caac.70041   Screening for Cervical Cancer (2026). Obstetrics & Gynecology, 148(1), e63-e67. https://doi.org/10.1097/AOG.0000000000006257  Jad Zeitouni, Nosayaba Osazuwa-Peters, Yusuf Dundar, Gregory Zimet, Mark A. Varvares. (2025). Two decades of the HPV vaccine: its promise, progress, prospects, projections, and posterity, The Lancet Regional Health - Americas, (51), https://doi.org/10.1016/j.lana.2025.101243 Diabetes, Obesity and Metabolism 28, no. 6 (2026): 5043–5057, https://doi.org/10.1111/dom.70698.  Relationship of early rapid weight loss to efficacy and safety of tirzepatide and semaglutide for obesity: SURMOUNT-5 post hoc analysis. Am J Med. 2026 Jul;139(7):913-921. doi: 10.1016/j.amjmed.2026.03.010 US Preventive Services Task Force; Nicholson WK, Silverstein M, Wong JB, et al. Screening for breast cancer: US Preventive Services Task Force recommendation statement. JAMA. 2024;331(22):1918–1930.  Trentham-Dietz A, Chapman CH, Jayasekera J, et al. Collaborative modeling to compare different breast cancer screening strategies: a decision analysis for the US Preventive Services Task Force. JAMA. 2024;331(22):1931–1946. Giaquinto AN, Sung H, Miller KD, et al. Breast cancer statistics, 2022. CA Cancer J Clin. 2022;72(6):524–541.  Qaseem A, Harrod CS, Balk EM, et al. Screening for breast cancer in asymptomatic, average-risk adult females: a guidance statement from the American College of Physicians (Version 2). Ann Intern Med. 2026.:  American Cancer Society. Breast Cancer Facts & Figures 2022–2024. Atlanta, GA: American Cancer Society, 2022.  Hu X, Chehal PK, Kaplan C, et al. Racial differences in patient-reported symptoms and adherence to adjuvant endocrine therapy among women with early-stage, hormone receptor-positive breast cancer. JAMA Netw Open. 2022;5(8):e2225485.  Torres JM, Sodipo MO, Hopkins MF, Chandler PD, Warner ET. Racial differences in breast cancer survival between Black and White women according to tumor subtype: a systematic review and meta-analysis. J Clin Oncol. 2024;42(35):4225–4234.  Bailey ZD, Krieger N, Agénor M, Graves J, Linos N, Bassett MT. Structural racism and health inequities in the USA: evidence and interventions. Lancet. 2017;389(10077):1453–1463. Hypertension. 2026;83:00–00. DOI: 10.1161/HYPERTENSIONAHA.125.25787 Allen RH, Bartz D. Opill: The Over-the-Counter Contraceptive Pill. Obstet Gynecol. 2024;143(2):184-188. doi:10.1097/AOG.0000000000005455  Cahill EP, Kaur S. Advances in contraception research and development. Curr Opin Obstet Gynecol. 2020;32(6):393-398. doi:10.1097/GCO.0000000000000666  Charles DN, Nagarsheth M, Oshman L. Pain Management for IUD Insertion in Primary Care. Am Fam Physician. 2025;111(4):299-301.  Chen, C., Strasser, J., Banawa, R., Luo, Q., Bodas, M., Castruccio-Prince, C., Das, K., & Pittman, P. (2022). Who is providing contraception care in the United States? An observational study of the contraception workforce. American journal of obstetrics and gynecology, 226(2), 232.e1–232.e11. https://doi.org/10.1016/j.ajog.2021.08.015  Diedrich,J., Klein, D. Peipert, J.(2017). Long-acting reversible contraception in adolescents: a systematic review and meta-analysis, Am J Ob Gyn, April 2017. http://dx.doi.org/10.1016/j.ajog.2016.12.024  Li RHW, Lo SST, Gemzell-Danielsson K, Fong CHY, Ho PC, Ng EHY. Oral emergency contraception with levonorgestrel plus piroxicam: a randomised double-blind placebo-controlled trial. Lancet. 2023;402(10405):851-858. doi:10.1016/S0140-6736(23)01240-0  Mørch LS, Meaidi A, Corn G, Hargreave M, Wessel Skovlund C. Breast Cancer in Users of Levonorgestrel-Releasing Intrauterine Systems. JAMA. 2024;332(18):1578–1580. doi:10.1001/jama.2024.18575  Nguyen AT, Curtis KM, Tepper NK, et al. U.S. Medical Eligibility Criteria for Contraceptive Use, 2024. MMWR Recomm Rep. 2024;73(4):1-126. Published 2024 Aug 8. doi:10.15585/mmwr.rr7304a1  Paradise SL, Landis CA, Klein DA. Evidence Based Contraception: Common Questions and Answers. American Family Physician. 2022. https://www.aafp.org/afp/2022/0900/contraception The views expressed in this podcast are those of Dr. Domino and his guests and do not necessarily reflect the views of Pri-Med.

Credits: 0.75 AMA PRA Category 1 Credit™   CME/CE Information and Claim Credit: https://www.pri-med.com/online-education/podcast/frankly-speaking-cme-500 Overview: To celebrate our 500th episode, each member of our team revisits a popular topic from the podcast's earlier installments—GLP-1s, cervical and breast cancer screening, diet and exercise, contraception, hypertension, and lipid management—to trace how the evidence and guidelines have changed since it was first covered. Whether you're catching up or reinforcing what you know, this milestone episode helps you bring the latest evidence into everyday patient care. Guest: Robert Baldor, MD, Alan Ehrlich, MD, Susan Feeney, DNP, FNP-BC; FAANP, Jillian Joseph, PA, Mariyan L. Montaque, DNP, FNP-BC, Jill Terrien PhD, ANP-BC, FAAN   Music Credit: Matthew Bugos Thoughts? Suggestions? Email us at FranklySpeaking@pri-med.com  Episode resource links:  Zhou H et al.  Evaluation and Comparison of the PREVENT and Pooled Cohort Equations for 10‐Year Atherosclerotic Cardiovascular Risk Prediction. Journal of the American Heart Association Volume 14, Number 4 Goff DC et al. 2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association task force on practice guidelines. Circulation. 2014;129:S49–S73. Circulation. 2018 Jul 24;138(4):345-355.  eClinicalMedicine 2025: 103741. Curry, J. (2018). Screening for cervical cancer: US Preventive Services Task Force Recommendation Statement. JAMA.320(7):674-686. doi:10.1001/jama.2018.10897 https://www.ncbi.nlm.nih.gov/pubmed/30140884  Perkins RB, Wolf AMD, Church TR, et al. Self-collected vaginal specimens for human papillomavirus testing and guidance on screening exit: An update to the American Cancer Society cervical cancer screening guideline. CA Cancer J Clin. 2026;e70041. doi:10.3322/caac.70041   Screening for Cervical Cancer (2026). Obstetrics & Gynecology, 148(1), e63-e67. https://doi.org/10.1097/AOG.0000000000006257  Jad Zeitouni, Nosayaba Osazuwa-Peters, Yusuf Dundar, Gregory Zimet, Mark A. Varvares. (2025). Two decades of the HPV vaccine: its promise, progress, prospects, projections, and posterity, The Lancet Regional Health - Americas, (51), https://doi.org/10.1016/j.lana.2025.101243 Diabetes, Obesity and Metabolism 28, no. 6 (2026): 5043–5057, https://doi.org/10.1111/dom.70698.  Relationship of early rapid weight loss to efficacy and safety of tirzepatide and semaglutide for obesity: SURMOUNT-5 post hoc analysis. Am J Med. 2026 Jul;139(7):913-921. doi: 10.1016/j.amjmed.2026.03.010 US Preventive Services Task Force; Nicholson WK, Silverstein M, Wong JB, et al. Screening for breast cancer: US Preventive Services Task Force recommendation statement. JAMA. 2024;331(22):1918–1930.  Trentham-Dietz A, Chapman CH, Jayasekera J, et al. Collaborative modeling to compare different breast cancer screening strategies: a decision analysis for the US Preventive Services Task Force. JAMA. 2024;331(22):1931–1946. Giaquinto AN, Sung H, Miller KD, et al. Breast cancer statistics, 2022. CA Cancer J Clin. 2022;72(6):524–541.  Qaseem A, Harrod CS, Balk EM, et al. Screening for breast cancer in asymptomatic, average-risk adult females: a guidance statement from the American College of Physicians (Version 2). Ann Intern Med. 2026.:  American Cancer Society. Breast Cancer Facts & Figures 2022–2024. Atlanta, GA: American Cancer Society, 2022.  Hu X, Chehal PK, Kaplan C, et al. Racial differences in patient-reported symptoms and adherence to adjuvant endocrine therapy among women with early-stage, hormone receptor-positive breast cancer. JAMA Netw Open. 2022;5(8):e2225485.  Torres JM, Sodipo MO, Hopkins MF, Chandler PD, Warner ET. Racial differences in breast cancer survival between Black and White women according to tumor subtype: a systematic review and meta-analysis. J Clin Oncol. 2024;42(35):4225–4234.  Bailey ZD, Krieger N, Agénor M, Graves J, Linos N, Bassett MT. Structural racism and health inequities in the USA: evidence and interventions. Lancet. 2017;389(10077):1453–1463. Hypertension. 2026;83:00–00. DOI: 10.1161/HYPERTENSIONAHA.125.25787 Allen RH, Bartz D. Opill: The Over-the-Counter Contraceptive Pill. Obstet Gynecol. 2024;143(2):184-188. doi:10.1097/AOG.0000000000005455  Cahill EP, Kaur S. Advances in contraception research and development. Curr Opin Obstet Gynecol. 2020;32(6):393-398. doi:10.1097/GCO.0000000000000666  Charles DN, Nagarsheth M, Oshman L. Pain Management for IUD Insertion in Primary Care. Am Fam Physician. 2025;111(4):299-301.  Chen, C., Strasser, J., Banawa, R., Luo, Q., Bodas, M., Castruccio-Prince, C., Das, K., & Pittman, P. (2022). Who is providing contraception care in the United States? An observational study of the contraception workforce. American journal of obstetrics and gynecology, 226(2), 232.e1–232.e11. https://doi.org/10.1016/j.ajog.2021.08.015  Diedrich,J., Klein, D. Peipert, J.(2017). Long-acting reversible contraception in adolescents: a systematic review and meta-analysis, Am J Ob Gyn, April 2017. http://dx.doi.org/10.1016/j.ajog.2016.12.024  Li RHW, Lo SST, Gemzell-Danielsson K, Fong CHY, Ho PC, Ng EHY. Oral emergency contraception with levonorgestrel plus piroxicam: a randomised double-blind placebo-controlled trial. Lancet. 2023;402(10405):851-858. doi:10.1016/S0140-6736(23)01240-0  Mørch LS, Meaidi A, Corn G, Hargreave M, Wessel Skovlund C. Breast Cancer in Users of Levonorgestrel-Releasing Intrauterine Systems. JAMA. 2024;332(18):1578–1580. doi:10.1001/jama.2024.18575  Nguyen AT, Curtis KM, Tepper NK, et al. U.S. Medical Eligibility Criteria for Contraceptive Use, 2024. MMWR Recomm Rep. 2024;73(4):1-126. Published 2024 Aug 8. doi:10.15585/mmwr.rr7304a1  Paradise SL, Landis CA, Klein DA. Evidence Based Contraception: Common Questions and Answers. American Family Physician. 2022. https://www.aafp.org/afp/2022/0900/contraception The views expressed in this podcast are those of Dr. Domino and his guests and do not necessarily reflect the views of Pri-Med.

This week on On The Pen, the GLP-1 story is moving in two very different directions.The Fifth Circuit handed FDA major wins in the fight over semaglutide and tirzepatide shortages, FDA updated its consumer guidance around compounded GLP-1 medications and multi-dose vials, and employers continue questioning whether they can afford obesity-drug coverage.At the same time, the medical case for these medications keeps getting stronger.We break down Mounjaro's new cardiovascular indication and what preventing heart attacks and strokes could mean for the true long-term cost of GLP-1 treatment. We also look at 600,000 Medicare beneficiaries already enrolling in the $50 GLP-1 Bridge program, California's effort to tackle affordability, the rapidly expanding oral GLP-1 market, and new real-world data on patients staying at lower doses of semaglutide and tirzepatide.The science is expanding. Access is contracting.And that may be the biggest challenge facing the next phase of the GLP-1 revolution.In this episode:• What the Fifth Circuit compounding decisions actually mean• FDA's updated language around compounded GLP-1 vials• The 28-day multi-dose vial controversy• Mounjaro's new cardiovascular indication• Why GLP-1s may reduce long-term healthcare costs• Employers dropping obesity-drug coverage• 600,000 people joining the Medicare GLP-1 Bridge• California's push for lower GLP-1 prices• The oral GLP-1 race• New data on lower-dose semaglutide and tirzepatideFollow everything On The Pen:This episode is sponsored by VoaFit.https://www.voafit.com/otpThis content is for informational and educational purposes only and is not medical advice. Always discuss medication and treatment decisions with a qualified healthcare professional.

This episode of ASN Kidney Translation Podcast explores the ASN Kidney Health Guidance on the Cardiovascular-Kidney-Metabolic (CKM) Syndrome, discussing key recommendations, risk assessment, and strategies to improve kidney, heart, and metabolic outcomes.

How does someone gain 20, 30, or even 40 pounds without really noticing it? Usually, it doesn't happen overnight. It happens a pound at a time. In today's episode, we're talking about something I call “creeping obesity”—the gradual weight gain that can occur when we add just one or two pounds a month, month after month, year after year.One pound doesn't seem like much. But one pound a month can become 12 pounds in a year and potentially 24 pounds in two years. Two pounds a month can become nearly 50 pounds over that same period.The good news is that the process can work in the opposite direction, too. Small improvements in your eating habits, caloric awareness, exercise, and daily activity can add up to remarkable changes over time. And instead of looking for another 30-day diet, we need to start thinking about where we want to be one or two years from now.In this episode, I'll explain how creeping obesity happens, why calories still matter, how resistance and cardiovascular training can help, and why working with a personal trainer can provide the structure, accountability, and guidance you need to reach your goals.The weight didn't appear overnight, and it doesn't have to disappear overnight.So let's stop the creep, start making better decisions, and discover what consistent effort can accomplish.Enjoy The EpisodeRead The Article

Credits: 0.75 AMA PRA Category 1 Credit™   CME/CE Information and Claim Credit: https://www.pri-med.com/online-education/podcast/frankly-speaking-cme-500 Overview: To celebrate our 500th episode, each member of our team revisits a popular topic from the podcast's earlier installments—GLP-1s, cervical and breast cancer screening, diet and exercise, contraception, hypertension, and lipid management—to trace how the evidence and guidelines have changed since it was first covered. Whether you're catching up or reinforcing what you know, this milestone episode helps you bring the latest evidence into everyday patient care. Guest: Robert Baldor, MD, Alan Ehrlich, MD, Susan Feeney, DNP, FNP-BC; FAANP, Jillian Joseph, PA, Mariyan L. Montaque, DNP, FNP-BC, Jill Terrien PhD, ANP-BC, FAAN   Music Credit: Matthew Bugos Thoughts? Suggestions? Email us at FranklySpeaking@pri-med.com  Episode resource links:  Zhou H et al.  Evaluation and Comparison of the PREVENT and Pooled Cohort Equations for 10‐Year Atherosclerotic Cardiovascular Risk Prediction. Journal of the American Heart Association Volume 14, Number 4 Goff DC et al. 2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association task force on practice guidelines. Circulation. 2014;129:S49–S73. Circulation. 2018 Jul 24;138(4):345-355.  eClinicalMedicine 2025: 103741. Curry, J. (2018). Screening for cervical cancer: US Preventive Services Task Force Recommendation Statement. JAMA.320(7):674-686. doi:10.1001/jama.2018.10897 https://www.ncbi.nlm.nih.gov/pubmed/30140884  Perkins RB, Wolf AMD, Church TR, et al. Self-collected vaginal specimens for human papillomavirus testing and guidance on screening exit: An update to the American Cancer Society cervical cancer screening guideline. CA Cancer J Clin. 2026;e70041. doi:10.3322/caac.70041   Screening for Cervical Cancer (2026). Obstetrics & Gynecology, 148(1), e63-e67. https://doi.org/10.1097/AOG.0000000000006257  Jad Zeitouni, Nosayaba Osazuwa-Peters, Yusuf Dundar, Gregory Zimet, Mark A. Varvares. (2025). Two decades of the HPV vaccine: its promise, progress, prospects, projections, and posterity, The Lancet Regional Health - Americas, (51), https://doi.org/10.1016/j.lana.2025.101243 Diabetes, Obesity and Metabolism 28, no. 6 (2026): 5043–5057, https://doi.org/10.1111/dom.70698.  Relationship of early rapid weight loss to efficacy and safety of tirzepatide and semaglutide for obesity: SURMOUNT-5 post hoc analysis. Am J Med. 2026 Jul;139(7):913-921. doi: 10.1016/j.amjmed.2026.03.010 US Preventive Services Task Force; Nicholson WK, Silverstein M, Wong JB, et al. Screening for breast cancer: US Preventive Services Task Force recommendation statement. JAMA. 2024;331(22):1918–1930.  Trentham-Dietz A, Chapman CH, Jayasekera J, et al. Collaborative modeling to compare different breast cancer screening strategies: a decision analysis for the US Preventive Services Task Force. JAMA. 2024;331(22):1931–1946. Giaquinto AN, Sung H, Miller KD, et al. Breast cancer statistics, 2022. CA Cancer J Clin. 2022;72(6):524–541.  Qaseem A, Harrod CS, Balk EM, et al. Screening for breast cancer in asymptomatic, average-risk adult females: a guidance statement from the American College of Physicians (Version 2). Ann Intern Med. 2026.:  American Cancer Society. Breast Cancer Facts & Figures 2022–2024. Atlanta, GA: American Cancer Society, 2022.  Hu X, Chehal PK, Kaplan C, et al. Racial differences in patient-reported symptoms and adherence to adjuvant endocrine therapy among women with early-stage, hormone receptor-positive breast cancer. JAMA Netw Open. 2022;5(8):e2225485.  Torres JM, Sodipo MO, Hopkins MF, Chandler PD, Warner ET. Racial differences in breast cancer survival between Black and White women according to tumor subtype: a systematic review and meta-analysis. J Clin Oncol. 2024;42(35):4225–4234.  Bailey ZD, Krieger N, Agénor M, Graves J, Linos N, Bassett MT. Structural racism and health inequities in the USA: evidence and interventions. Lancet. 2017;389(10077):1453–1463. Hypertension. 2026;83:00–00. DOI: 10.1161/HYPERTENSIONAHA.125.25787 Allen RH, Bartz D. Opill: The Over-the-Counter Contraceptive Pill. Obstet Gynecol. 2024;143(2):184-188. doi:10.1097/AOG.0000000000005455  Cahill EP, Kaur S. Advances in contraception research and development. Curr Opin Obstet Gynecol. 2020;32(6):393-398. doi:10.1097/GCO.0000000000000666  Charles DN, Nagarsheth M, Oshman L. Pain Management for IUD Insertion in Primary Care. Am Fam Physician. 2025;111(4):299-301.  Chen, C., Strasser, J., Banawa, R., Luo, Q., Bodas, M., Castruccio-Prince, C., Das, K., & Pittman, P. (2022). Who is providing contraception care in the United States? An observational study of the contraception workforce. American journal of obstetrics and gynecology, 226(2), 232.e1–232.e11. https://doi.org/10.1016/j.ajog.2021.08.015  Diedrich,J., Klein, D. Peipert, J.(2017). Long-acting reversible contraception in adolescents: a systematic review and meta-analysis, Am J Ob Gyn, April 2017. http://dx.doi.org/10.1016/j.ajog.2016.12.024  Li RHW, Lo SST, Gemzell-Danielsson K, Fong CHY, Ho PC, Ng EHY. Oral emergency contraception with levonorgestrel plus piroxicam: a randomised double-blind placebo-controlled trial. Lancet. 2023;402(10405):851-858. doi:10.1016/S0140-6736(23)01240-0  Mørch LS, Meaidi A, Corn G, Hargreave M, Wessel Skovlund C. Breast Cancer in Users of Levonorgestrel-Releasing Intrauterine Systems. JAMA. 2024;332(18):1578–1580. doi:10.1001/jama.2024.18575  Nguyen AT, Curtis KM, Tepper NK, et al. U.S. Medical Eligibility Criteria for Contraceptive Use, 2024. MMWR Recomm Rep. 2024;73(4):1-126. Published 2024 Aug 8. doi:10.15585/mmwr.rr7304a1  Paradise SL, Landis CA, Klein DA. Evidence Based Contraception: Common Questions and Answers. American Family Physician. 2022. https://www.aafp.org/afp/2022/0900/contraception The views expressed in this podcast are those of Dr. Domino and his guests and do not necessarily reflect the views of Pri-Med.

Credits: 0.75 AMA PRA Category 1 Credit™   CME/CE Information and Claim Credit: https://www.pri-med.com/online-education/podcast/frankly-speaking-cme-500 Overview: To celebrate our 500th episode, each member of our team revisits a popular topic from the podcast's earlier installments—GLP-1s, cervical and breast cancer screening, diet and exercise, contraception, hypertension, and lipid management—to trace how the evidence and guidelines have changed since it was first covered. Whether you're catching up or reinforcing what you know, this milestone episode helps you bring the latest evidence into everyday patient care. Guest: Robert Baldor, MD, Alan Ehrlich, MD, Susan Feeney, DNP, FNP-BC; FAANP, Jillian Joseph, PA, Mariyan L. Montaque, DNP, FNP-BC, Jill Terrien PhD, ANP-BC, FAAN   Music Credit: Matthew Bugos Thoughts? Suggestions? Email us at FranklySpeaking@pri-med.com  Episode resource links:  Zhou H et al.  Evaluation and Comparison of the PREVENT and Pooled Cohort Equations for 10‐Year Atherosclerotic Cardiovascular Risk Prediction. Journal of the American Heart Association Volume 14, Number 4 Goff DC et al. 2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association task force on practice guidelines. Circulation. 2014;129:S49–S73. Circulation. 2018 Jul 24;138(4):345-355.  eClinicalMedicine 2025: 103741. Curry, J. (2018). Screening for cervical cancer: US Preventive Services Task Force Recommendation Statement. JAMA.320(7):674-686. doi:10.1001/jama.2018.10897 https://www.ncbi.nlm.nih.gov/pubmed/30140884  Perkins RB, Wolf AMD, Church TR, et al. Self-collected vaginal specimens for human papillomavirus testing and guidance on screening exit: An update to the American Cancer Society cervical cancer screening guideline. CA Cancer J Clin. 2026;e70041. doi:10.3322/caac.70041   Screening for Cervical Cancer (2026). Obstetrics & Gynecology, 148(1), e63-e67. https://doi.org/10.1097/AOG.0000000000006257  Jad Zeitouni, Nosayaba Osazuwa-Peters, Yusuf Dundar, Gregory Zimet, Mark A. Varvares. (2025). Two decades of the HPV vaccine: its promise, progress, prospects, projections, and posterity, The Lancet Regional Health - Americas, (51), https://doi.org/10.1016/j.lana.2025.101243 Diabetes, Obesity and Metabolism 28, no. 6 (2026): 5043–5057, https://doi.org/10.1111/dom.70698.  Relationship of early rapid weight loss to efficacy and safety of tirzepatide and semaglutide for obesity: SURMOUNT-5 post hoc analysis. Am J Med. 2026 Jul;139(7):913-921. doi: 10.1016/j.amjmed.2026.03.010 US Preventive Services Task Force; Nicholson WK, Silverstein M, Wong JB, et al. Screening for breast cancer: US Preventive Services Task Force recommendation statement. JAMA. 2024;331(22):1918–1930.  Trentham-Dietz A, Chapman CH, Jayasekera J, et al. Collaborative modeling to compare different breast cancer screening strategies: a decision analysis for the US Preventive Services Task Force. JAMA. 2024;331(22):1931–1946. Giaquinto AN, Sung H, Miller KD, et al. Breast cancer statistics, 2022. CA Cancer J Clin. 2022;72(6):524–541.  Qaseem A, Harrod CS, Balk EM, et al. Screening for breast cancer in asymptomatic, average-risk adult females: a guidance statement from the American College of Physicians (Version 2). Ann Intern Med. 2026.:  American Cancer Society. Breast Cancer Facts & Figures 2022–2024. Atlanta, GA: American Cancer Society, 2022.  Hu X, Chehal PK, Kaplan C, et al. Racial differences in patient-reported symptoms and adherence to adjuvant endocrine therapy among women with early-stage, hormone receptor-positive breast cancer. JAMA Netw Open. 2022;5(8):e2225485.  Torres JM, Sodipo MO, Hopkins MF, Chandler PD, Warner ET. Racial differences in breast cancer survival between Black and White women according to tumor subtype: a systematic review and meta-analysis. J Clin Oncol. 2024;42(35):4225–4234.  Bailey ZD, Krieger N, Agénor M, Graves J, Linos N, Bassett MT. Structural racism and health inequities in the USA: evidence and interventions. Lancet. 2017;389(10077):1453–1463. Hypertension. 2026;83:00–00. DOI: 10.1161/HYPERTENSIONAHA.125.25787 Allen RH, Bartz D. Opill: The Over-the-Counter Contraceptive Pill. Obstet Gynecol. 2024;143(2):184-188. doi:10.1097/AOG.0000000000005455  Cahill EP, Kaur S. Advances in contraception research and development. Curr Opin Obstet Gynecol. 2020;32(6):393-398. doi:10.1097/GCO.0000000000000666  Charles DN, Nagarsheth M, Oshman L. Pain Management for IUD Insertion in Primary Care. Am Fam Physician. 2025;111(4):299-301.  Chen, C., Strasser, J., Banawa, R., Luo, Q., Bodas, M., Castruccio-Prince, C., Das, K., & Pittman, P. (2022). Who is providing contraception care in the United States? An observational study of the contraception workforce. American journal of obstetrics and gynecology, 226(2), 232.e1–232.e11. https://doi.org/10.1016/j.ajog.2021.08.015  Diedrich,J., Klein, D. Peipert, J.(2017). Long-acting reversible contraception in adolescents: a systematic review and meta-analysis, Am J Ob Gyn, April 2017. http://dx.doi.org/10.1016/j.ajog.2016.12.024  Li RHW, Lo SST, Gemzell-Danielsson K, Fong CHY, Ho PC, Ng EHY. Oral emergency contraception with levonorgestrel plus piroxicam: a randomised double-blind placebo-controlled trial. Lancet. 2023;402(10405):851-858. doi:10.1016/S0140-6736(23)01240-0  Mørch LS, Meaidi A, Corn G, Hargreave M, Wessel Skovlund C. Breast Cancer in Users of Levonorgestrel-Releasing Intrauterine Systems. JAMA. 2024;332(18):1578–1580. doi:10.1001/jama.2024.18575  Nguyen AT, Curtis KM, Tepper NK, et al. U.S. Medical Eligibility Criteria for Contraceptive Use, 2024. MMWR Recomm Rep. 2024;73(4):1-126. Published 2024 Aug 8. doi:10.15585/mmwr.rr7304a1  Paradise SL, Landis CA, Klein DA. Evidence Based Contraception: Common Questions and Answers. American Family Physician. 2022. https://www.aafp.org/afp/2022/0900/contraception The views expressed in this podcast are those of Dr. Domino and his guests and do not necessarily reflect the views of Pri-Med.

What questions do you have about GLP-1 medications and weight loss? In this episode of Back on Track: Achieving Healthy Weight Loss, I'm doing something a little different. I'm answering five real questions that viewers have left on my YouTube videos and social media about weight loss medications. I'll talk about whether you can take Contrave with a GLP-1, whether GLP-1 medications are an option if you have hypothyroidism or Hashimoto's disease, and whether it's safe to increase your dose faster if you aren't experiencing side effects. I'll also explain what to do if you need to change your injection day or miss a dose, and how to think about calorie intake when you're trying to lose weight. These are questions I hear frequently, and I want to give you a better understanding of the issues to discuss with your own healthcare provider. This podcast is for education only, and because I don't know your individual medical history, it's important to talk with your own doctor about what's right for you. Episode Highlights: Can Contrave can be taken with a GLP-1 How Contrave may help with hunger, cravings, and food noise GLP-1 medications and hypothyroidism or Hashimoto's disease Which thyroid conditions are contraindications for GLP-1 medications Why I recommend starting at a low dose and increasing slowly How I decide when it may be time for a patient to increase their dose What to do if you need to change your GLP-1 injection day What happens if you miss a GLP-1 dose Why eating too little can work against your weight-loss efforts How the NIH Body Weight Planner can help you determine your calorie needs Why fueling your body with balanced meals is important during weight loss And this is just Part 1. In Part 2 of Ask the Obesity Doctor, I'll answer more questions about GLP-1 safety, compounded and counterfeit medications, black-market peptides, medication interactions, side effects, and "Ozempic face." If you're using a GLP-1 medication, considering one, or simply have questions about weight loss medications, I hope these answers help you have a more informed conversation with your healthcare provider. Connect with Dr. Alicia Shelly Website | drshellymd.com Facebook | www.facebook.com/drshellymd Instagram | @drshellymd Linked In | www.linkedin.com/in/drshellymd Twitter | @drshellymd About Dr. Alicia Shelly Dr. Alicia Shelly was raised in Atlanta, GA. She received her Doctorate of Medicine from Case Western Reserve University School of Medicine in Cleveland, OH.  Dr. Shelly has been practicing Primary Care and Obesity medicine since 2014.  In 2017, she became a Diplomat of the American Board of Obesity Medicine. She is the lead physician at the Wellstar Medical Center Douglasville. She started a weekly podcast & Youtube channel entitled Back on Track: Achieving Healthy Weight loss,  where she discusses how to get on track and stay on track with your weight loss journey. She has spoken for numerous local and national organizations, including the Obesity Medicine Association, and the Georgia Chapter of the American Society of Metabolic and Bariatric Surgeons. She has been featured on CNN, Fox 5 News, Bruce St. James Radio show, Upscale magazine, and Shape.com. She was named an honoree of the 2021 Atlanta Business Chronicle's 40 under 40 award. She also is a collaborating author for the, "Made for More: Physician Entrepreneurs who Live Life and Practice Medicine on their own terms''. Resources: FREE! Discover the 5 Reasons Your Weight-Loss Journey Has Gotten Derailed (And How To Get Back On Track!)

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/NCPD/AAPA information, and to apply for credit, please visit us at PeerView.com/PWH865. CME/NCPD/AAPA credit will be available until August 16, 2027.Treating Beyond the Scale: Personalized, Evidence-Based Strategies for Comprehensive Management of Obesity as a Chronic Disease In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Lilly.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/NCPD/AAPA information, and to apply for credit, please visit us at PeerView.com/PWH865. CME/NCPD/AAPA credit will be available until August 16, 2027.Treating Beyond the Scale: Personalized, Evidence-Based Strategies for Comprehensive Management of Obesity as a Chronic Disease In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Lilly.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/NCPD/AAPA information, and to apply for credit, please visit us at PeerView.com/PWH865. CME/NCPD/AAPA credit will be available until August 16, 2027.Treating Beyond the Scale: Personalized, Evidence-Based Strategies for Comprehensive Management of Obesity as a Chronic Disease In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Lilly.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/NCPD/AAPA information, and to apply for credit, please visit us at PeerView.com/PWH865. CME/NCPD/AAPA credit will be available until August 16, 2027.Treating Beyond the Scale: Personalized, Evidence-Based Strategies for Comprehensive Management of Obesity as a Chronic Disease In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Lilly.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/NCPD/AAPA information, and to apply for credit, please visit us at PeerView.com/PWH865. CME/NCPD/AAPA credit will be available until August 16, 2027.Treating Beyond the Scale: Personalized, Evidence-Based Strategies for Comprehensive Management of Obesity as a Chronic Disease In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Lilly.Disclosure information is available at the beginning of the video presentation.

Dr. Christian Rodriguez joins the show straight from Pennington Biomedical, where he works alongside obesity research legends Eric Ravussin and Steve Heymsfield. He breaks down his new review on metabolically healthy obesity and why the old "zero metabolic syndrome criteria" definitions are so inconsistent. The conversation dives deep into the Lancet Commission's new obesity framework, comparing it to the ACE staging system and picking apart where each one falls short, including the controversial call to leave type 2 diabetes out of the "preclinical" category. Rodriguez also previews his upcoming study on people with a BMI of 60 and above, a group that's rarely studied because researchers aren't sure it's safe. The episode wraps with a candid discussion on GLP-1 stigma and why treating obesity early matters more than chasing a number on the scale. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Food as Medicine: Why Medical Nutrition Therapy and Medically Tailored Meals Belong in Modern Healthcare: Registered dietitian nutritionist Leyla Muedin argues that food should be treated with the same rigor as medication through medical nutrition therapy (MNT) and “diet prescriptions,” integrating nutrition into treatment plans rather than leaving it as optional advice. She cites evidence that medically tailored meals (MTMs) can improve outcomes and reduce costs, including a Health Affairs simulation estimating $23.7B in first-year net savings nationwide and a Nature Medicine analysis of a Massachusetts Medicaid demonstration (2020–2023) showing MTM recipients had 31% fewer hospitalizations, 20% fewer emergency visits, and $3,433 lower total healthcare costs, offsetting 98% of program costs. She discusses food insecurity, expanding Medicaid coverage via Section 1115 waivers, EHR integration, and how MTMs support adherence for conditions such as diabetes, cardiovascular disease, chronic kidney disease, depression, and IBS (including low FODMAP).

How a vegan turned to a No-Oil diet and reversed her diabetes in this reprise of the PETA Podcast. See more about Stephanie's story at PETA.org.  

A Phase III win for a melanoma vaccine from Moderna and Merck & Co. has opened the door to personalized neoantigen vaccines. On the latest BioCentury This Week podcast, BioCentury's analysts discuss the vaccine's prospects and the broader implications. The analysts also discuss Roche/Genentech's deal with Hanmi, which will add to the MNC's obesity pipeline an asset that the pharma believes could be first in class, and the White House's pick of a Trump loyalist to lead FDA – a move that has revived questions of the agency's independence.View full story: https://www.biocentury.com/article/660596#CancerVaccines #Obesity #FDA #Oncology #DrugDevelopment00:00 - Introduction03:03 - Moderna11:12 - Genentech obesity deal15:08 - Trump's FDA pickTo submit a question to BioCentury's editors, email the BioCentury This Week team at podcasts@biocentury.com.Reach us by sending a text

EWhat if the experiences you want to forget are connected to the purpose you are searching for? In this episode, Daniel Lloyd shares his story of addiction, mental health struggles, trauma, shame, relationships, and recovery. He explains how lived experience shaped his understanding of connection, intuition, personal responsibility, and life purpose. Daniel challenges the idea that your past has to define your future. He explains why taking ownership of your choices matters, how shame affects people struggling with addiction and mental health, and why connection plays such a major role in recovery. The conversation also explores intuition, early-life experiences, personal transformation, finding purpose through pain, and creating a specific vision for your future. Daniel shares his vision of helping 11 million people find their smile again and explains how he turned years of personal struggle into a clear sense of purpose.  In this episode, you'll learn: • How pain and lived experience can shape your sense of purpose • Why taking responsibility changes the way you approach your life • How shame affects addiction and mental health • Why Daniel sees addiction as a medical issue rather than a moral failure • How connection relates to addiction and recovery • How early experiences influenced Daniel's beliefs about himself • Why reframing your experiences matters • How to create a specific vision for your future • Why your past does not have to determine your next chapter • How intuition connects with self-awareness and personal growth • Why finding your purpose starts with understanding your own story Daniel's story shows how years of struggle became part of the work he does today. He believes purpose often sits inside your pain, where your lived experience becomes something you can use to help others. Connect with Daniel Lloyd: Facebook: https://www.facebook.com/danny.lloyd.10  Linkedin: www.linkedin.com/in/daniel-lloyd-384385a4  Instagram: @insideout_coach.official Connect with Doug Beitz: Email: info@dougbeitz.com Facebook: https://www.facebook.com/dougbeitz/ Instagram: https://www.instagram.com/dougbeitz/ Website: https://buymeacoffee.com/dougbeitz Spotify: https://open.spotify.com/show/6mQ258nugC3lyw3SpvYuoK?si=7cec409527d34438 Apple Podcasts: https://podcasts.apple.com/au/podcast/intuitive-conversations-with-doug/id1593172364 LinkedIn: https://www.linkedin.com/in/doug-beitz-472a4b338/ TikTok: https://www.tiktok.com/@dougbeitz178

The effects of obesity caused by western junk food diets can be passed to children through their dad's sperm. Research by the University of Auckland's Liggins institute suggests what the father is eating could, in some cases, be more influential than mother's diets, which has long been a focus. Senior research fellow Dr Ben Albert spoke to Lisa Owen.

Do you ever wonder how medications like Wegovy and Mounjaro influence your metabolic health? Dr. Emily Cooper, along with Andrea Taylor and Mark Wright, dives into listener questions about maintaining metabolic health when medication coverage is lost, understanding the role of leptin after weight loss, and the effects of medications like Mounjaro. They also explore the injection site reactions and the complex interplay between thyroid, exercise, and inflammation.KEY TAKEAWAYSLoss of medication insurance coverage can significantly impact treatment, but alternative options like pills may be available.Leptin levels differ by gender; they're naturally lower in men due to different body composition.Fasting can disrupt hunger signals and glucose regulation, particularly following intermittent fasting.Injection site reactions are common but switching medications or techniques might alleviate symptoms.NOTABLE QUOTE"Obesity is a physical sign of underlying metabolic dysfunction." — Dr. Emily CooperLINKS & RESOURCESTo register for course: https://learn.diabesityinstitute.org/products/live_events/live-virtual-update-eventLinks & ResourcesPodcast Home: fatsciencepodcast.comCooper Center for Metabolism: coopermetabolic.comResources from Dr. Cooper: coopermetabolic.com/resourcesJoin Our Community: patreon.com/cw/FatSciencePodcastSubmit Your Question: questions@fatsciencepodcast.com or dr.c@fatsciencepodcast.comFat Science is supported by the Diabesity Institute, a nonprofit dedicated to increasing access to effective, science-based metabolic care.This podcast is for informational purposes only and is not intended as medical advice. Please consult with a qualified healthcare provider for personalized recommendations.

One month into the Medicare GLP-1 Bridge program, I've learned that getting approved is less complicated once you understand the pathway. But there are several important details that can cause delays if you don't know what to look for. In this episode, I walk you through what I've learned from helping patients navigate the Medicare GLP-1 Bridge during its first month. We cover who qualifies, which medications and formulations are included, when you may need to use Medicare Part D instead, and what your doctor, pharmacy, and you need to do to keep the process moving. I'll also explain why your current BMI may not be the BMI that matters, why the pharmacy claim needs to happen before the prior authorization, and why staying engaged with both your pharmacy and doctor's office can make a difference. And once you actually get your medication, I shift the conversation to what you should be doing to maximize your results, including getting adequate protein, moving your body, strength training, and staying engaged with your medical team. If you're trying to navigate the Medicare GLP-1 Bridge program for yourself or a loved one, this episode will help you understand the process and the questions you need to ask. Episode Highlights: ● What the Medicare GLP-1 Bridge program is and how it differs from Medicare Part D ● The three main eligibility pathways for the Bridge program ● Why your BMI when you started GLP-1 therapy may matter more than your current BMI ● When certain medical conditions may require you to use the regular Medicare Part D pathway ● Why having eligible Medicare Part D coverage matters ● Which GLP-1 medications and formulations are included in the Bridge program ● Why the correct Zepbound formulation matters ● What your pharmacy needs from your Medicare information ● Why the pharmacy claim needs to happen before the prior authorization ● How to follow up when your prescription seems stuck in the process ● What to focus on once you actually receive your medication ● Why protein, exercise, strength training, and medical follow-up remain important ● What we currently know about what happens when the Bridge program ends   Connect with Dr. Alicia Shelly Website | drshellymd.com Facebook | www.facebook.com/drshellymd Instagram | @drshellymd Linked In | www.linkedin.com/in/drshellymd Twitter | @drshellymd About Dr. Alicia Shelly Dr. Alicia Shelly was raised in Atlanta, GA. She received her Doctorate of Medicine from Case Western Reserve University School of Medicine in Cleveland, OH.  Dr. Shelly has been practicing Primary Care and Obesity medicine since 2014.  In 2017, she became a Diplomat of the American Board of Obesity Medicine. She is the lead physician at the Wellstar Medical Center Douglasville. She started a weekly podcast & Youtube channel entitled Back on Track: Achieving Healthy Weight loss,  where she discusses how to get on track and stay on track with your weight loss journey. She has spoken for numerous local and national organizations, including the Obesity Medicine Association, and the Georgia Chapter of the American Society of Metabolic and Bariatric Surgeons. She has been featured on CNN, Fox 5 News, Bruce St. James Radio show, Upscale magazine, and Shape.com. She was named an honoree of the 2021 Atlanta Business Chronicle's 40 under 40 award. She also is a collaborating author for the, "Made for More: Physician Entrepreneurs who Live Life and Practice Medicine on their own terms''. Resources: FREE! Discover the 5 Reasons Your Weight-Loss Journey Has Gotten Derailed (And How To Get Back On Track!)

Do you suffer with anxiety, depression, or another mental illness? Millions of people do. The usual treatment is a prescription medication. If that doesn't work, the healthcare provider may offer a different one. Diet is certainly not the first topic on the provider's mind. But what if, in addition to appropriate pharmacological treatment, you were able to nourish, protect and energize your brain with your diet? Our guest offers evidence that you can heal your mind with a ketogenic approach to eating. We need to acknowledge that this approach is quite different from the plant-rich eating pattern advocated by last week's guest, Dr. Will Bulsiewicz. Humans around the world have adopted a wide range of dietary regimens that support health. Listen to Dr. Georgia Ede explain why she thinks a paleo or ketogenic diet is helpful for bolstering brain health. At The People's Pharmacy, we strive to bring you up to date, rigorously researched insights and conversations about health, medicine, wellness and health policies and health systems. While these conversations intend to offer insight and perspective, the content is provided solely for informational and educational purposes. Please consult your healthcare provider before making any changes to your medical care or treatment. How You Can Listen You could listen through your local public radio station or get the live stream at 7 am EST on Saturday, August 22, 2026, through your computer or smart phone (wunc.org). Here is a link so you can find which stations carry our broadcast. If you can't listen to the broadcast, you may wish to hear the podcast later. You can subscribe through your favorite podcast provider, download the mp3 using the link at the bottom of the page, or listen to the stream on this post starting on August 24, 2026. Can You Heal Your Brain with Food? We live in stressful times. More than 50 million Americans take prescription antidepressants, and millions more are on anti-anxiety medication. Unfortunately, while these drugs can be life savers, they don't always work as well as we would like. In some cases, antidepressants are only about 10 percent more effective than a placebo. Dr. Georgia Ede is a psychiatrist who began her investigation into how food affects mental health serendipitously. She was experimenting with her own diet to address some physical health issues. She used a food and symptom journal to discover the best dietary choices for her own health. To her surprise, the “upside-down” diet that helped her feel better physically also improved her sleep and her ability to focus. She started looking into evidence that a paleo or ketogenic diet could benefit people with mental health challenges. What Is Metabolic Psychiatry? There is evidence that people consuming unhealthy diets full of fast food or ultra-processed products are more susceptible to symptoms of anxiety (Nutrition Neuroscience, May 19, 2026). On the other hand, people participating in a supervised weight-loss program using either a low-carbohydrate ketogenic diet or a low-fat diet reported improvements in mood (Obesity, Jan. 2007). Those on the ketogenic (Atkins) diet reported less hunger and fewer unpleasant symptoms. Researchers have also tested a ketogenic diet in people with schizophrenia or bipolar disorder (Psychiatry Research, May 2024).  These volunteers also had metabolic disorders, including obesity, which is often an unwanted effect of the ant-psychotic drugs they take to treat their condition. This four-month pilot study saw participants lose weight, reduce insulin resistance and lower their triglycerides. Even more impressive, they had a 32 percent reduction in the Brief Psychiatric Rating Scale. They also reported better sleep and improved life satisfaction. You may find this recent article from National Geographic of interest: https://www.nationalgeographic.com/health/article/metabolic-psychiatry-keto-diet-brain-science. Unfortunately, it might be behind a paywall. How Does Food Affect Our Brains? Most of our body tissues are accustomed to getting energy from glucose, with the help of insulin. However, years of exposure to high levels of these compounds often makes the tissues less sensitive to the effects of insulin. The consequence is that the body–and therefore also the brain–is flooded with high levels of glucose. This exposure can result in the formation of advanced glycation end products in the brain, which can be harmful. The brain evolved to use either glucose or a flexible mix of glucose and ketones. These are the result of burning fat rather than sugar. A paleo diet will naturally provide more ketones and less glucose. Dr. Ede and colleagues have found that a ketogenic diet can be very helpful even for people with relatively serious mental problems. In one study (which was not placebo-controlled), patients hospitalized with severe persistent mental illness were given a ketogenic diet. Most did well and had significant improvements in their depression and psychosis symptoms (Frontiers in Psychiatry, July 6, 2022). Is Ketosis Dangerous? Ketosis itself simply means that you are burning fat as fuel rather than sugar. This can be achieved by following a diet that is high in animal fat, with moderate amounts of animal protein and low amounts of carbohydrate derived from plant foods. Ketosis is not inherently dangerous. However, Dr. Ede urges anyone who wants to heal their brain with diet to ask a healthcare provider to monitor and supervise the process. Prescription drug doses may require adjustment, and people may need support as they adopt a paleo or ketogenic diet. That is why this is not a do-it-yourself approach. Is Coconut Oil Helpful to Heal Your Brain? Dr. Ede described the benefits of medium-chain fatty acids produced in digesting fat. You may recall a video from a few years back in which a doctor described helping her husband recover from Alzheimer disease, at least partially, by giving him coconut oil. Some researchers consider Alzheimer disease to be a form of diabetes because the AD brain does not metabolize sugar effectively. Dr. Ede suggested that the benefits may be real, but getting medium-chain fatty acids from the diet rather than be taking coconut oil might be preferable. After Dr. Ede told us about Fran, who overcame significant memory problems by changing to a ketogenic diet, we hope there will be trials on this. Future Trials on Diet to Heal Your Brain Dietary trials are notoriously difficult to conduct. People often don't stick to the prescribed diet, and it can be difficult to find an appropriate placebo for comparison. Nonetheless, Dr. Ede is looking forward to results from a large trial of the keto diet for people with schizophrenia or bipolar disorder. This study is being conducted in Australia. This Week’s Guest Dr. Georgia Ede is a globally recognized expert in nutritional and metabolic psychiatry. Her 25+ years of clinical experience include 7 years at Harvard University, where she was the first psychiatrist to offer nutrition-based approaches to mental health conditions. Dr. Ede co-authored the first inpatient study of the ketogenic diet for serious mental illness, developed the first medically accredited course in ketogenic diets for mental health, and is a recipient of the Baszucki Metabolic Mind Award. Current research collaborations include pilot studies in pediatric bipolar disorder, adult ADHD, and PTSD. Her internationally bestselling book Change Your Diet, Change Your Mind: A Powerful Plan to Improve Mood, Overcome Anxiety, and Protect Memory for a Lifetime of Optimal Mental Health is being translated into 11 languages and is recommended by the New York Times Book Review. The People's Pharmacy is reader supported. When you buy through links in this post, we may earn a small affiliate commission (at no cost to you). Dr. Georgia Ede, author of Change Your Diet, Change Your Mind Listen to the Podcast The podcast of this program will be available Monday, August 24, 2026, after broadcast on Aug. 22. In this week's podcast, we'll learn how vegetarians can follow a ketogenic diet. How does the evidence Dr. Ede has collected accord with the chemical imbalance theory of mental illness? We also discuss why the standard American diet is not good for mental wellbeing, and we find out what might be in Dr. Ede's own shopping cart. You can stream the show from this site and download the podcast for free. Download the mp3, or listen to the podcast on Apple Podcasts or Spotify.

There's a hidden fat that matters more for your health than your weight.  This is visceral fat: it wraps around your organs, raises your risk of heart disease and cancer, and builds up even in people who look slim and healthy.  In today's episode, Professor Jimmy Bell, a world-leading expert in measuring visceral fat, explains how we can shrink this dangerous belly fat in just 12 weeks. Jimmy explores why two people can weigh exactly the same and carry completely different amounts of this hidden fat, what it is, where it hides and why it matters. By the end, you'll have a completely new understanding of body fat, and what it really means for your long-term health. If your weight has stayed exactly the same for years, what do you think is happening underneath it?

P.M. Edition for Aug. 10. The FDA has laid out new rules intended to make the food system more transparent, part of an overhaul promised by Health Secretary Robert F. Kennedy Jr. WSJ reporter Liz Essley Whyte discusses how the new rules would work and why guidelines for ultraprocessed foods didn't come today. Plus, as Iran strengthens its demands in negotiations to reopen the Strait of Hormuz, Gulf states have begun accepting a new reality: that Tehran will control the strait for the foreseeable future. We hear from WSJ Middle East correspondent Benoit Faucon about what they are doing about it. And more than 70 people have been killed in a 7.4 magnitude earthquake in Colombia. Alex Ossola hosts. Sign up for the WSJ's free What's News newsletter. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode the guys break down 5 easy ways to fix obesity that are sustainable long term — injecting more movement into your daily life in small ways, avoiding hyper-palatable drug-like processed foods, lifting weights occasionally (even just once or twice a week is enough), connecting through activity with friends and community, and turning off social media an hour before bed. They also discuss the obesity epidemic now hitting Italian kids as processed food arrived, the milkshake study on how belief changes physical response, Adam's internal battle between ego and caution while squatting, Sal's dad performing CPR for 15 minutes on a motorcycle accident victim, pneumatic gym equipment and why it beats traditional machines for explosive training, the Brick phone device Sal and his wife are using to block social media before bed, the sauna temperature and longevity data deep dive, and Butcher Box egg bites and the best things in their lineup. Then they answer questions from Instagram.   Paleo Valley (organ complex): https://paleovalley.com/mindpump 15% off automatically applied at checkout. Organ complex discussed on air — freeze dried liver, heart and kidney capsules, nature's multivitamin.   Butcher Box: https://butcherbox.com/mindpump No code needed. Free ribeyes, NY strip steaks or filet mignons in every order for a year plus $20 off first box. Egg bites and tater tots discussed on air.   Our Place (non-toxic cookware): https://fromourplace.com Code: MINDPUMP for 10% off sitewide. Always Pan replaces 8 pieces of cookware. Forever chemical free, 100-day trial, free returns.   LINKS   Mind Pump Store: https://mindpumpstore.com Maps Fitness Products: https://mapsfitnessproducts.com Instagram: @mindpumpmedia   SPOTIFY TIMESTAMPS   0:00 - Intro 2:15 - 5 easy ways to fix obesity for the long term 2:46 - Tip 1: Walk more — pair it with habits you already have instead of scheduling workouts 10:57 - Tip 2: Avoid drug-like foods — processed food eaters consume 600 more calories per day in studies 16:03 - Tip 3: Lift weights occasionally — even 1-2 days a week produces dramatic results 19:31 - Tip 4: Connect through activity — community is the number one predictor of consistency 22:02 - Tip 5: Turn off social media an hour before bed — the Brick device Sal is using 32:33 - Paleo Valley organ complex — nature's multivitamin and who Sal recommended it to 34:28 - Italian kids obesity epidemic — how processed food arrived late and hit hard 38:03 - The milkshake study — how belief changes physical response 40:16 - Adam's internal battle under the bar — ego vs. caution vs. longevity 45:43 - Pneumatic gym equipment — why Kaiser machines are better for power training 49:58 - Adam cheated on Katrina in her dream and she's still processing it 56:24 - Sauna temperature and longevity data — the Finnish study and what the data actually shows 1:09:41 - Q&A: Best way to come off a GLP-1 and reverse diet 1:14:15 - Q&A: Can you gain mostly fat instead of muscle during a bulk if you overtrain? 1:15:32 - Q&A: How much training volume is optimal in a calorie deficit? 1:18:15 - Q&A: Best advice to remain patient and trust the process